Skip Navigation
Skip to contents

JLC : Journal of Liver Cancer

OPEN ACCESS
SEARCH
Search

Previous issues

Page Path
HOME > Articles and issues > Previous issues
16 Previous issues
Filter
Filter
Article category
Volume 24(1); March 2024
Prev issue Next issue
Editorial
Radiofrequency for hepatocellular carcinoma larger than 3 cm: potential for applications in daily practice
Ji Hoon Kim, Pil Soo Sung
J Liver Cancer. 2024;24(1):1-2.   Published online March 14, 2024
DOI: https://doi.org/10.17998/jlc.2024.02.13
  • 3,920 Views
  • 114 Downloads
PDF
Close layer
Correspondences
Close layer
Reply to the Letter regarding “Treatment options for solitary hepatocellular carcinoma ≤5 cm: surgery vs. ablation: a multicenter retrospective study”
Kazuhiro Nouso, Kazuya Kariyama
J Liver Cancer. 2024;24(1):5-6.   Published online January 19, 2024
DOI: https://doi.org/10.17998/jlc.2024.01.02
  • 3,077 Views
  • 70 Downloads
PDF
Close layer
Performance of HCC diagnosis in the KLCA-NCC guidelines: a closer look at MRI contrast agents and HCC imaging hallmarks
Ji Hye Min, Young Kon Kim
J Liver Cancer. 2024;24(1):7-8.   Published online November 6, 2023
DOI: https://doi.org/10.17998/jlc.2023.10.08
  • 3,810 Views
  • 110 Downloads
PDF
Close layer
Review Articles
Complications of immunotherapy in advanced hepatocellular carcinoma
Young-Gi Song, Jeong-Ju Yoo, Sang Gyune Kim, Young Seok Kim
J Liver Cancer. 2024;24(1):9-16.   Published online November 29, 2023
DOI: https://doi.org/10.17998/jlc.2023.11.21
  • 14,050 Views
  • 305 Downloads
  • 24 Web of Science
  • 25 Citations
AbstractAbstract PDF
Immune checkpoint inhibitors (ICIs) are highly effective in cancer treatment. However, the risks associated with the treatment must be carefully balanced against the therapeutic benefits. Immune-related adverse events (irAEs) are generally unpredictable and may persist over an extended period. In this review, we analyzed common irAEs reported in highly cited original articles and systematic reviews. The prevalent adverse reactions include fatigue, pyrexia, rash, pruritus, diarrhea, decreased appetite, nausea, abdominal pain, constipation, hepatitis, and hypothyroidism. Therefore, it is crucial to conduct evaluations not only of gastrointestinal organs but also of cardiac, neurologic, endocrine (including the frequently affected thyroid), and ophthalmic systems before commencing ICIs. This review further explores commonly reported types of irAEs, specific irAEs associated with each ICI agent, rare yet potentially fatal irAEs, and available treatment options for managing them.

Citations

Citations to this article as recorded by  
  • Efficacy and Safety of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
    Muhammad A.B. Naeem, Muhammad R. Paracha, Ahmad Noor, Muhammad H.A. Khalid, Hafiza K. Shahid, Maaz Khan, Moeaza R. Rizvi, Javeeria Arshad, Talha Abbas, Azeem Saeed, Hamza Ashraf, Minahil Ali, Mishal Asif, Aanusha Ghouri
    American Journal of Clinical Oncology.2026; 49(4): 196.     CrossRef
  • Advances in the Therapeutic Landscape of Hepatocellular Carcinoma: Current Strategies and Future Perspectives
    Asahiro Morishita, Kyoko Oura, Hiroki Tai, Rie Yano, Mai Nakahara, Tomoko Tadokoro, Koji Fujita, Shima Mimura, Joji Tani, Miwa Tatsuta, Takashi Himoto, Hideki Kobara
    Cancers.2026; 18(4): 609.     CrossRef
  • Immunotherapy in hepatocellular carcinoma: translating mechanistic insights into clinical advances
    Saeed Khavari Khorasani, Siavash Boroumandi, Ali Darzi, Mahla Shokouhfar, Pedram Abdali, Pooya Eini, Ahmad Ghorbani Vanan, Nastaran Bahrami
    Clinical and Experimental Medicine.2026;[Epub]     CrossRef
  • Clinical efficacy of immunotherapy in combination of locoregional therapies for advanced hepatocellular carcinoma: a systematic review and meta-analysis
    Xinyue Chen, Mohan Huang, Ranran Liu, Lawrence Wing Chi Chan
    Frontiers in Immunology.2026;[Epub]     CrossRef
  • Nivolumab plus ipilimumab for hepatocellular carcinoma: a game-changer?
    Lorenza Di Marco, Federica Valerio, Yuri Maculan, Bianca Medici, Andrea Spallanzani, Massimo Dominici, Angela Dalia Ricci, Alessandro Rizzo, Massimiliano Salati
    Expert Opinion on Biological Therapy.2026; 26(3): 257.     CrossRef
  • Expert consensus on the use of immune checkpoint inhibitors in the liver transplant setting: Guidance from the Liver Transplant Committee of the Italian Association for the Study of the Liver (AISF)
    Francesca Romana Ponziani, Valerio Giannelli, Giuseppe Marrone, Silvia Martini, Maria Cristina Morelli, Duilio Pagano, Gianluca Svegliati Baroni, Giacomo Germani, Patrizia Burra, Pierluigi Toniutto
    American Journal of Transplantation.2026; 26(8): 1946.     CrossRef
  • Immune-related adverse events in hepatocellular carcinoma: organ-specific patterns and management approaches
    Sul Ki Choi, Seonjeong Woo, Hong Jae Chon
    Journal of Liver Cancer.2026; 26(1): 65.     CrossRef
  • Liver Stiffness Measured by Vibration-Controlled Transient Elastography Predicts Hepatic Decompensation in Patients with Hepatocellular Carcinoma Receiving Systemic Treatments
    Jaejun Lee, Hyun Yang, Si Hyun Bae, Hee Sun Cho, Pil Soo Sung, Jeong Won Jang, Seung Kew Yoon, Keungmo Yang, Heechul Nam, Chang Wook Kim, Hae Lim Lee, Hee Yeon Kim, Sung Won Lee, Ahlim Lee, Do Seon Song, Seok Hwan Kim, Myung Jun Song, Soon Kyu Lee, Jung H
    Liver Cancer.2026; : 1.     CrossRef
  • Electronic symptom monitoring of patient-reported outcomes among patients with hepatocellular carcinoma during immunotherapy (PRIME-HCC): protocol for a randomised controlled trial
    Yiqi Xia, Xiaoping Wei, Yanshang Wang, Zhenyu Shi, Ping He
    BMJ Open.2026; 16(5): e116199.     CrossRef
  • Machine learning based hepatic safety score predicts decompensation in hepatocellular carcinoma systemic therapy
    Ji Won Han, Jaejun Lee, Keungmo Yang, Kwon Yong Tak, Hyun Yang, Si Hyun Bae, Hee Sun Cho, Heechul Nam, Chang Wook Kim, Hae Lim Lee, Hee Yeon Kim, Sung Won Lee, Ahlim Lee, Do Seon Song, Seok Hwan Kim, Myeong Jun Song, Soon Woo Nam, Soon Kyu Lee, Jung Hyun
    npj Digital Medicine.2026;[Epub]     CrossRef
  • Regorafenib combined with programmed death inhibitor after initial treatment failure in unresectable hepatocellular carcinoma
    Fei Ma, Li-Yun Zheng, Dan-Jun Song, Zhong-Wei Zhao, Fei Cao, Wei-Yuan Hao, Jun-Qi Qiu, Dong Lu, Jia-Ping Zheng
    World Journal of Gastrointestinal Oncology.2026;[Epub]     CrossRef
  • METTL3-mediated SMPDL3A promotes cell growth, metastasis and immune process of hepatocellular carcinoma by regulating LRPPRC
    Weixin Xu, Miaomiao Tao, Yeqiong Liu, Jun Yan, Jiali Hu, Lei Wang
    Cellular Signalling.2025; 127: 111543.     CrossRef
  • Case Report: A rare small bowel sarcoma
    Jiwu Guo, Jie Mao
    Frontiers in Surgery.2025;[Epub]     CrossRef
  • Disparate patterns of disease time burden in patients with HCC on immunotherapy or tyrosine kinase inhibitors
    Rex Wan-Hin Hui, Matthew Shing-Hin Chung, Lu Li, Xianhua Mao, Chi-Leung Chiang, Carlos King-Ho Wong, Ian Chi-Kei Wong, Ka-Shing Cheung, Man-Fung Yuen, Wai-Kay Seto, Lung-Yi Mak
    JHEP Reports.2025; 7(11): 101578.     CrossRef
  • Navigating the Therapeutic Pathway and Optimal First-Line Systemic Therapy for Hepatocellular Carcinoma in the Era of Immune Checkpoint Inhibitors
    Hyun Phil Shin, Moonhyung Lee
    Medicina.2025; 61(12): 2164.     CrossRef
  • Successful Treatment of Nivolumab Plus Ipilimumab After Progression on Durvalumab Plus Tremelimumab in Advanced Hepatocellular Carcinoma: A Case Report
    Akinori Sasaki, Rika kimura, Risa Okamoto
    Cureus.2025;[Epub]     CrossRef
  • Radiotherapy Combined with Immune Checkpoint Inhibitor on Murine Fibrosarcoma and a Narrative Review of Clinical Studies
    Wonwoo Kim, Hyunkyung Kim, Won Il Jang, Mi Sook Kim, Sun Hyun Bae
    Current Issues in Molecular Biology.2025; 48(1): 20.     CrossRef
  • Intrahepatic IgA complex induces polarization of cancer-associated fibroblasts to matrix phenotypes in the tumor microenvironment of HCC
    Jong Geun Park, Pu Reun Roh, Min Woo Kang, Sung Woo Cho, Suhyun Hwangbo, Hae Deok Jung, Hyun Uk Kim, Ji Hoon Kim, Jae-Sung Yoo, Ji Won Han, Jeong Won Jang, Jong Young Choi, Seung Kew Yoon, Young Kyoung You, Ho Joong Choi, Jae Yong Ryu, Pil Soo Sung
    Hepatology.2024; 80(5): 1074.     CrossRef
  • Risk of Bleeding in Hepatocellular Carcinoma Patients Treated with Atezolizumab/Bevacizumab: A Systematic Review and Meta-Analysis
    Young-Gi Song, Kyeong-Min Yeom, Eun Ae Jung, Sang Gyune Kim, Young Seok Kim, Jeong-Ju Yoo
    Liver Cancer.2024; : 1.     CrossRef
  • Targeted therapies in hepatocellular carcinoma: past, present, and future
    Rushabh Gujarathi, Joseph W. Franses, Anjana Pillai, Chih-Yi Liao
    Frontiers in Oncology.2024;[Epub]     CrossRef
  • Atezolizumab-Induced Ulcerative Colitis in Patient with Hepatocellular Carcinoma: Case Report and Literature Review
    Hyuk Kim, Yoon E Shin, Hye-Jin Yoo, Jae-Young Kim, Jeong-Ju Yoo, Sang Gyune Kim, Young Seok Kim
    Medicina.2024; 60(9): 1422.     CrossRef
  • A Potential Pneumothorax Induced by Immune Checkpoint Inhibitors: A Case Report and Literature Review
    Yoon-E Shin, Hyuk Kim, Jeong-Ju Yoo, Sang Gyune Kim, Young Seok Kim
    Medicina.2024; 60(10): 1634.     CrossRef
  • The histopathological and molecular heterogeneity of hepatocellular carcinoma: a narrative review
    Wonju Chung, Haeryoung Kim
    The Ewha Medical Journal.2024;[Epub]     CrossRef
  • Pathogenesis and management of metabolic dysfunction-associated steatohepatitis-related hepatocellular carcinoma: a narrative review
    Han Ah Lee
    The Ewha Medical Journal.2024;[Epub]     CrossRef
  • Current perspectives on the pharmacological treatment of advanced hepatocellular carcinoma: a narrative review
    Hye-Jin Yoo, Jeong-Ju Yoo, Sang Gyune Kim, Young Seok Kim
    The Ewha Medical Journal.2024;[Epub]     CrossRef
Close layer
Intrahepatic cholangiocarcinoma: histological diversity and the role of the pathologist
Mina Komuta
J Liver Cancer. 2024;24(1):17-22.   Published online January 3, 2024
DOI: https://doi.org/10.17998/jlc.2023.12.11
  • 18,145 Views
  • 479 Downloads
  • 9 Web of Science
  • 10 Citations
AbstractAbstract PDF
Intrahepatic cholangiocarcinoma (iCCA) is one of the primary liver cancers and presents with tumor heterogeneity. About 50% of iCCAs comprise actionable mutations, which completely change patient management. In addition, the precise diagnosis of iCCA, including subtype, has become crucial, and pathologists play an important role in this regard. This review focuses on iCCA heterogeneity; looking at different perspectives to guide diagnosis and optimal treatment choice.

Citations

Citations to this article as recorded by  
  • Refinement of histologic subtypes and identification of biomarkers linked to unfavorable prognosis in cholangiocarcinoma: The ENSCCA registries’ framework for digital twin advancement
    Guido Carpino, Diletta Overi, Rocio I.R. Macias, Vincenzo Cardinale, Laura Izquierdo-Sanchez, Pilar Acedo, Marco Rengo, Michail Doukas, Timothy J. Kendall, Julien Calderaro, Lara R. Heij, Konrad Reichel, Stefano Leone, Paolo Onori, Barbara Franceschini, C
    Hepatology.2026; 83(4): 753.     CrossRef
  • Surgical management of intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma: a narrative review of principles, technical nuances, and emerging strategies
    Woohyung Lee, Kwang Pyo Hong, Jae Hoon Lee, Mirang Lee, Minkyu Sung, Seung Jae Lee, Ki Byung Song, Dae Wook Hwang, Song Cheol Kim
    Journal of Liver Cancer.2026; 26(1): 19.     CrossRef
  • Standardization of Gross Examination in Histopathology: A Literature-based Comparative Review of Domestic and International Reporting Guidelines
    Kyungbae LEE, Woohyun JI, Sanghoon CHOI
    Korean Journal of Clinical Laboratory Science.2026; 58(2): 233.     CrossRef
  • Development of a preoperative prediction model for non-curative resection in intrahepatic cholangiocarcinoma involving the hepatic hilum
    Xinming Li, Yaoqun Wang, Jiaqi Yang, Jiong Lu
    European Journal of Surgical Oncology.2026; 52(10): 112061.     CrossRef
  • Targeting the cGAS–STING Pathway in Gastrointestinal Cancers: Modulating Tumor-associated Inflammation for Therapeutic Effect
    Heena Rathod, Parag Jain, Deepika Verma, Karan Kumar Dharme, Gyaneshwari Verma, Ajazuddin
    Current Drug Targets.2026; 27(9): 600.     CrossRef
  • Trends and Disparities in Intrahepatic Cholangiocarcinoma-related Mortality in the United States from 1999 to 2020
    Obaid Ur Rehman, Malik Saad Hayat, Muhammad Mukarram Shoaib, Eeman Ahmad, Zain Ali Nadeem, Ahmad Zain
    Journal of Gastrointestinal Cancer.2025;[Epub]     CrossRef
  • Small but significant: Prognostic value of the small duct type in intrahepatic cholangiocarcinoma
    Jiyun Kim, Joon Young Park, So Young Kim, Sejin Jung, Joo-Young Na, Hyun Jung Lee, Dong Hoon Shin, Jung Hee Lee
    Annals of Diagnostic Pathology.2025; 79: 152515.     CrossRef
  • From barriers to solutions: an expert-based algorithm for cholangiocarcinoma and other biliary tract cancers testing in the Era of precision oncology
    Albrecht Stenzinger, Nicola Normanno, Angela Lamarca, Lorenza Rimassa, Fréderic Bibeau, Philippe Taniere, Arndt Vogel, Antoine Hollebecque
    Expert Review of Molecular Diagnostics.2025; 25(8): 495.     CrossRef
  • Role of Radiation Therapy for Biliary Tract Cancers
    Molly A. Chakraborty, Ritesh Kumar, Brett L. Ecker, Haejin In, Russell C. Langan, Mariam Eskander, Salma K. Jabbour
    Current Oncology.2025; 32(10): 545.     CrossRef
  • Imaging findings of intrahepatic cholangiocarcinoma for prognosis prediction and treatment decision-making: a narrative review
    Jun Gu Kang, Taek Chung, Dong Kyu Kim, Hyungjin Rhee
    The Ewha Medical Journal.2024;[Epub]     CrossRef
Close layer
Intermediate-stage hepatocellular carcinoma: refining substaging or shifting paradigm?
Bernardo Stefanini, Luca Ielasi, Dante Pio Pallotta, Sofia Penazza, Mariarosaria Marseglia, Fabio Piscaglia
J Liver Cancer. 2024;24(1):23-32.   Published online March 12, 2024
DOI: https://doi.org/10.17998/jlc.2024.02.21
  • 19,330 Views
  • 472 Downloads
  • 9 Web of Science
  • 7 Citations
AbstractAbstract PDF
This review explores the evolution of cancer staging, focusing on intermediate hepatocellular carcinoma (HCC), and the challenges faced by physicians. The Barcelona Clinic Liver Cancer (BCLC) staging system, introduced in 1999, was designed to address the limitations associated with providing accurate prognostic information for HCC and allocating specific treatments, to avoid overtreatment. However, criticism has emerged, particularly regarding the intermediate stage of HCC (BCLC-B) and its heterogeneous patient population. To overcome this limitation, various subclassification systems, such as the Bolondi and Kinki criteria, have been proposed. These systems are aimed at refining categorizations within the intermediate stage and have demonstrated varying degrees of success in predicting outcomes through external validation. This study discusses the shift in treatment paradigms, emphasizing the need for a more personalized approach rather than strictly adhering to cancer stages, without dismissing the relevance of staging systems. It assesses the available treatment options for intermediate-stage HCC, highlighting the importance of considering surgical and nonsurgical options alongside transarterial chemoembolization for optimal outcomes. In conclusion, the text advocates for a paradigm shift in staging systems prioritizing treatment suitability over cancer stage. This reflects the evolving landscape of HCC management, where a multidisciplinary approach is crucial for tailoring treatments to individual patients, ultimately aiming to improve overall survival.

Citations

Citations to this article as recorded by  
  • A demethylation-driven gene signature predicts prognosis and therapeutic vulnerability in hepatocellular carcinoma
    Zhengwei Wang, Lei Shi, Yongjian Li, Sikai Liu, Wanyin Shi
    Scientific Reports.2026;[Epub]     CrossRef
  • Prognostic value of serum aldo-keto reductase family 1 member B10 in hepatocellular carcinoma
    Yun-Ling Du, Chang-Jiang Shi, Fang-Yuan Gao, Shou-Jun Xie, Meng-Na Zhang, Zhu-Qing Zhang, Wei Qiu, Ying Ming
    World Journal of Gastrointestinal Surgery.2026;[Epub]     CrossRef
  • Usefulness of preoperative peripheral blood GPC3‐positive circulating tumor cells in subclassification of Barcelona Clinic Liver Cancer stage B hepatocellular carcinoma: a retrospective cohort study
    Yosuke Namba, Tsuyoshi Kobayashi, Yoshito Hirata, Takeshi Tadokoro, Sotaro Fukuhara, Ko Oshita, Naruhiko Honmyo, Ryosuke Nakano, Hiroshi Sakai, Seiichi Shimizu, Shintaro Kuroda, Hiroyuki Tahara, Masahiro Ohira, Kentaro Ide, Yuka Tanaka, Hideki Ohdan
    Hepatology Research.2025; 55(8): 1172.     CrossRef
  • Potential anticancer therapeutic targets of resveratrol and its role in the therapy of hepatocellular carcinoma
    Wasnaa H. Mohammed, Ghassan M. Sulaiman, Hamdoon A. Mohammed
    Food Bioscience.2025; 69: 106935.     CrossRef
  • Role of immune checkpoint inhibitor combinations in resectable and unresectable, embolization-eligible hepatocellular carcinoma
    Brandon M. Meyers, Howard J. Lim, Mayur Brahmania, Dave M. Liu, Vincent C. Tam, Deanna McLeod, Ravi Ramjeesingh, Jennifer J. Knox, Arndt Vogel
    Therapeutic Advances in Medical Oncology.2025;[Epub]     CrossRef
  • Conversion Resection or Direct Resection for Patients with Intermediate-Stage Hepatocellular Carcinoma: A Multicentre Study
    Ying Zhou, Haiqing Wang, Jiayi Wu, Junyi Shen, Ji Ma, Qiu Li, Weixia Chen, Wusheng Lu, Xielin Feng, Maolin Yan, Tianfu Wen, Xiaoyun Zhang
    Liver Cancer.2025; : 1.     CrossRef
  • The Neoangiogenic Transcriptomic Signature Impacts Hepatocellular Carcinoma Prognosis and Can Be Triggered by Transarterial Chemoembolization Treatment
    Rosina Maria Critelli, Federico Casari, Alberto Borghi, Grazia Serino, Cristian Caporali, Paolo Magistri, Annarita Pecchi, Endrit Shahini, Fabiola Milosa, Lorenza Di Marco, Alessandra Pivetti, Simone Lasagni, Filippo Schepis, Nicola De Maria, Francesco Di
    Cancers.2024; 16(20): 3549.     CrossRef
Close layer
Current perspectives on radiotherapy in hepatocellular carcinoma management: a comprehensive review
Dowook Kim, Jun-Sang Kim
J Liver Cancer. 2024;24(1):33-46.   Published online March 25, 2024
DOI: https://doi.org/10.17998/jlc.2024.02.26
  • 20,839 Views
  • 601 Downloads
  • 9 Web of Science
  • 10 Citations
AbstractAbstract PDF
This review examines the transformative role of external beam radiotherapy (EBRT) in managing hepatocellular carcinoma (HCC), spotlighting the progression from traditional EBRT techniques to advanced modalities like intensity-modulated radiotherapy (RT), stereotactic body RT (SBRT), and innovative particle therapy, including proton beam therapy and carbon ion RT. These advancements have significantly improved the precision and efficacy of RT, marking a paradigm shift in the multimodal management of HCC, particularly in addressing complex cases and enhancing local tumor control. The review underscores the synergistic potential of integrating RT with other treatments like transarterial chemoembolization, systemic therapies such as sorafenib, and emerging immunotherapies, illustrating enhanced survival and disease control outcomes. The efficacy of RT is addressed for challenging conditions, including advanced HCC with macrovascular invasion, and RT modalities, like SBRT, are compared against traditional treatments like radiofrequency ablation for early-stage HCC. Additionally, the review accentuates the encouraging outcomes of particle therapy in enhancing local control and survival rates, minimizing treatment-related toxicity, and advocating for continued research and clinical trials. In conclusion, the integration of RT into multimodal HCC treatment strategies, coupled with the emergence of particle therapy, is crucial for advancing oncologic management, emphasizing the need for relentless innovation and personalized treatment approaches.

Citations

Citations to this article as recorded by  
  • Precision Radiation Therapy for Hepatocellular Carcinoma: Exploring the Clinical Utility of Functional Liver Avoidance Planning
    Afua A. Yorke, Matthew J. Nyflot, Smith Apisarnthanarax, Patty A. Sponseller, Stephen R. Bowen
    Practical Radiation Oncology.2026; 16(6): e547.     CrossRef
  • Breaking Barriers in Hepatocellular Carcinoma: Synergistic Potential of Stereotactic Body Radiotherapy Combined With Immunotherapy
    Deepti Sharma, Babu Lal Meena, Divya Khosla
    Journal of Clinical and Experimental Hepatology.2026; 16(5): 103593.     CrossRef
  • Natural phenolic compounds as modulators of radiation response in hepatocellular carcinoma
    Amirhossein Imani, Fatemeh B. Rassouli
    Clinical and Experimental Medicine.2026;[Epub]     CrossRef
  • Treatment of intermediate-to-advanced unresectable hepatocellular carcinoma is shifting toward a multidisciplinary strategy that includes multiple modalities as needed
    Ken Sato
    World Journal of Gastroenterology.2025;[Epub]     CrossRef
  • Development and Validation of Monte Carlo Methods for Converay: A Proof-of-Concept Study
    Rodolfo Figueroa, Francisco Malano, Alejandro Cuadra, Jaime Guarda, Jorge Leiva, Fernando Leyton, Adlin López, Claudio Solé, Mauro Valente
    Cancers.2025; 17(7): 1189.     CrossRef
  • A Comparative Analysis of the Roles of von Willebrand Factor and ADAMTS13 in Hepatocellular Carcinoma: A Bioinformatics and Microarray-Based Study
    Durmuş Ayan, Şerife Buket Bozkurt Polat, Ergül Bayram, Esma Özmen, Fatma Esin Aydın, Serpil Ersan
    Current Issues in Molecular Biology.2025; 47(4): 270.     CrossRef
  • Evaluation of the LI-RADS radiation treatment response assessment v2024 in comparison with the modified RECIST
    Hokun Kim, Bohyun Kim, Seok Hyun Son, Jeong Won Jang, Pil Soo Sung, Joon-Il Choi, Suho Kim, Jung Suk Oh, Ho Jong Chun
    European Radiology.2025; 35(12): 7549.     CrossRef
  • Primary small cell-like hepatocellular carcinoma arising in a patient with fatty liver disease without cirrhosis: a case report and literature review
    Hyun Bin Choi, Jeong-Ju Yoo, Susie Chin, Sang Gyune Kim, Young-Seok Kim
    Gastroenterology Report.2025;[Epub]     CrossRef
  • Efficacy of Radiotherapy in Combination with Immune Checkpoint Blockade for Hepatocellular Carcinoma and Portal Vein Tumor Thrombosis
    Yunjeong Lee, Minkyung Park, Eun Sun Jang, Gwanghyun Choi, Sook-Hyang Jeong, Jin Won Kim, Minsu Kang, Jee Hyun Kim, Changhoon Song, Kyubo Kim, Jin-Wook Kim
    The Korean Journal of Medicine.2025; 100(5): 252.     CrossRef
  • The research perspectives and frontiers on radiotherapy for hepatocellular carcinoma: a bibliometric analysis and systematic review
    Tao He, Hong Xiao, Bin Yi, Chengyan Zhou, Juan Yang, Ke Sun, Jieyu Zou
    Frontiers in Oncology.2025;[Epub]     CrossRef
Close layer
Multidisciplinary approach for hepatocellular carcinoma patients: current evidence and future perspectives
Joo Hyun Oh, Dong Hyun Sinn
J Liver Cancer. 2024;24(1):47-56.   Published online March 25, 2024
DOI: https://doi.org/10.17998/jlc.2024.02.27
  • 15,358 Views
  • 377 Downloads
  • 33 Web of Science
  • 34 Citations
AbstractAbstract PDF
Management of hepatocellular carcinoma (HCC) is challenging due to the complex relationship between underlying liver disease, tumor burden, and liver function. HCC is also notorious for its high recurrence rate even after curative treatment for early-stage tumor. Liver transplantation can substantially alter patient prognosis, but donor availability varies by each patient which further complicates treatment decision. Recent advancements in HCC treatments have introduced numerous potentially efficacious treatment modalities. However, high level evidence comparing the risks and benefits of these options is limited. In this complex situation, multidisciplinary approach or multidisciplinary team care has been suggested as a valuable strategy to help cope with escalating complexity in HCC management. Multidisciplinary approach involves collaboration among medical and health care professionals from various academic disciplines to provide comprehensive care. Although evidence suggests that multidisciplinary care can enhance outcomes of HCC patients, robust data from randomized controlled trials are currently lacking. Moreover, the implementation of a multidisciplinary approach necessitates increased medical resources compared to conventional cancer care. This review summarizes the current evidence on the role of multidisciplinary approach in HCC management and explores potential future directions.

Citations

Citations to this article as recorded by  
  • Therapeutic Strategies for Hepatocellular Carcinoma: Current Advances and Future Perspectives
    Palaniyandi Muthukutty, Jeong Heo, So Young Yoo
    Vaccines.2026; 14(2): 189.     CrossRef
  • The Role of the Multidisciplinary Team in the Management of Complex Cases of Liver Disease in a Peripheral Hospital: A Retrospective Analysis of MDT Registry
    Gabriele A. Vassallo, Tommaso Dionisi, Angelo Randazzo, Antonio Limblici, Monica Failla, Marcella Ferraro, Oriana Maiorana, Eleonora Taibi, Filomena Pietrantonio, Francesca Brovelli, Giovanni Addolorato, Giuseppe Augello
    Health Science Reports.2026;[Epub]     CrossRef
  • Using period analysis to timely provide serial data on long-term survival for liver cancer patients from China
    Pengtao Chen, Wei Gu, Xin Bing, Liangyou Wang, Yongran Cheng, Xukai Chen, Dinghu Zhang, Tianhui Chen
    Frontiers in Oncology.2026;[Epub]     CrossRef
  • Hepatocellular carcinoma: current aspects of multidisciplinary management. Part 2. Treatment and prevention
    Yu.M. Stepanov, N.Yu. Zavhorodnia, O.M. Vlasova
    GASTROENTEROLOGY.2026; 60(1): 52.     CrossRef
  • Multidisciplinary Clinic Approach Improves Immunotherapy Treatment Outcomes in Unresectable Hepatocellular Carcinoma: A Multicentre Retrospective Study
    Andrea Dalbeni, Alessandra Auriemma, Marco Vicardi, Filippo Cattazzo, Maria Elena Bellucco, Chiara Mazzarelli, Federica Villa, Giulia Dispinzieri, Leonardo Antonio Natola, Caterina Soldà, Sara Lonardi, Luisa Foltran, Sara Torresan, Simone Rota, Tiziana Pr
    Liver Cancer.2026; : 1.     CrossRef
  • Prognostic significance of neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in hepatocellular carcinoma: a retrospective multicenter study on overall and recurrence-free survival following liver resection or liver transplantation
    Konstantinos Arvanitakis, Spyridon Pantzios, Chrysanthos Christou, Vasileios Papadopoulos, Eleni Theocharidou, Christos Topalidis, Georgios Kalopitas, Orestis Sidiropoulos, Antonios Chatzigeorgiou, Ioannis Mitroulis, Triantafyllia Koletsa, Prodromos Hytir
    Frontiers in Immunology.2026;[Epub]     CrossRef
  • Integrating Network Pharmacology and Clinical Observation to Elucidate the Therapeutic Mechanisms of Yangzheng Xiaoji Decoction in Primary Liver Cancer
    Shengbo Yang, Rui Liu, Shuai Wen, Ya Wang, Nan Tai, Jie Tian
    International Journal of General Medicine.2026; Volume 19: 1.     CrossRef
  • Pharmaceutical Compounding as a Pillar of Personalized Oncology: Current Applications, Emerging Technologies, and Future Perspectives
    Filipa Mascarenhas-Melo, Rafael Pinheiro, Francis Victor, Maria Eugénia Pina, Ana Figueiras
    Pharmaceuticals.2026; 19(7): 1077.     CrossRef
  • Comparative Analysis of Albumin-Bilirubin (ALBI) Score and Child-Pugh Score for Prognostic Stratification in Hepatocellular Carcinoma Patients: A Single-Center Experience From North India
    Varun Goel, Arpit Jain, Nivedita Patnaik, Dharmishtha A Basu, Prateek Gupta, Shaifali Goel, Pankaj Goel, Vineet Talwar, Shivendra Singh
    Cureus.2026;[Epub]     CrossRef
  • Open, laparoscopic, and robotic liver resection for hepatocellular carcinoma: evolving roles, comparative outcomes, and future perspectives
    Jacopo Mascherini, Mira Khaldoun Eid, Garnet Vanterpool, Iswanto Sucandy
    Frontiers in Oncology.2026;[Epub]     CrossRef
  • Outcomes by Comorbidities with Tremelimumab and Durvalumab in the Randomized, Controlled Phase 3 HIMALAYA Study in Unresectable Hepatocellular Carcinoma
    Lorenza Rimassa, Farshid Dayyani, Robin K. Kelley, Bruno Sangro, Stephen L. Chan, Hitomi Nakamura, Lucy Clark, Ioannis Xynos, Ghassan K. Abou-Alfa
    Liver Cancer.2026; : 1.     CrossRef
  • IHPBA 2026 Global guideline for the management of hepatocellular carcinoma in resource-constrained healthcare settings.
    Ajith K. Siriwardena, Eduard Jonas, Glenn Bonney, Shridhar Iyer, John Primrose, Rafik Filobbos, Paleswan Lakhey, T.Peter Kingham, Mehan Siriwardhane, Elijah Dixon, Mariano E. Gimenez, Rohan Jeyarajah, Jose Manuel Ramia, Javier Lendoire, Tian Qian Song, Fr
    HPB.2026;[Epub]     CrossRef
  • Evolving practices, treatment decisions, and unmet needs in intermediate-stage hepatocellular carcinoma: An Asia Pacific perspective
    Suebpong Tanasanvimon, Pin-Nan Cheng, Wonseok Kang, Gwo-Fuang Ho, Tuan-Anh Pham, Michael Cabato, Ryan Edbert Husni, Bo-Young Kim, Pierce Chow
    World Journal of Gastrointestinal Oncology.2026;[Epub]     CrossRef
  • Teaching design for chapter “primary liver cancer” in surgery course based on the clinical theory and clerkship synchronization model in the era of New Medicine
    Feng Ye, Qiang Cai, Xiaoyong Gong, Jiajun Ren, Ruixin Sun, Chang Liu, Xiaoli Wang, Yuan Qiao
    Global Medical Education.2025; 2(1): 149.     CrossRef
  • Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment
    Soo Young Hwang, Pojsakorn Danpanichkul, Vatche Agopian, Neil Mehta, Neehar D. Parikh, Ghassan K. Abou-Alfa, Amit G. Singal, Ju Dong Yang
    Clinical and Molecular Hepatology.2025; 31(Suppl): S228.     CrossRef
  • Roadmap for HCC Surveillance and Management in the Asia Pacific
    Masatoshi Kudo, Bui Thi Oanh, Chien-Jen Chen, Do Thi Ngat, Jacob George, Do Young Kim, Luckxawan Pimsawadi, Pisit Tangkijvanich, Raoh-Fang Pwu, Rosmawati Mohamed, Sakarn Bunnag, Sheng-Nan Lu, Sirintip Kudtiyakarn, Tatsuya Kanto, Teerha Piratvisuth, Chao-C
    Cancers.2025; 17(12): 1928.     CrossRef
  • Assessment prior to liver tumor resection: what a radiologist needs to know
    Mahmoud Diab, Mindy X. Wang, Aarya Ramprasad, Ann A. Shi, Imran Ahmed, Sergio Klimkowski, Vincenzo K. Wong, Khaled M. Elsayes
    Abdominal Radiology.2025; 51(3): 1261.     CrossRef
  • Multidisciplinary Team Management of Hepatocellular Carcinoma in the MENA Region: Current Practices, Challenges, and Gaps
    Mohamed El-Kassas, Rofida Khalifa, Khalid AlNaamani, Hend Shousha, Yusuf Yilmaz, Faisal Sanai, Maen Almattooq, Asma Labidi, Maisam Akroush, Nabil Debzi, Mohamed Abdelmalek, Nermeen Abdeen, Ali Tumi, Mohamed Elbadry, Amr El Fouly, Eman Marwan, Jassim Al Su
    Journal of Hepatocellular Carcinoma.2025; Volume 12: 1315.     CrossRef
  • Advancing explainable AI in healthcare: Necessity, progress, and future directions
    Rashmita Kumari Mohapatra, Lochan Jolly, Sarada Prasad Dakua
    Computational Biology and Chemistry.2025; 119: 108599.     CrossRef
  • Primary small cell-like hepatocellular carcinoma arising in a patient with fatty liver disease without cirrhosis: a case report and literature review
    Hyun Bin Choi, Jeong-Ju Yoo, Susie Chin, Sang Gyune Kim, Young-Seok Kim
    Gastroenterology Report.2025;[Epub]     CrossRef
  • Advancements in nanoultrasonics technology for the diagnosis and treatment of liver cancer: discussion on medical ethics and hospital management issues
    Weiping Wan, Fan Yang, Yenan Zhang, Jie Wang, Xin Xie, Fangming Guo, Li Han
    Nanomedicine.2025; 20(21): 2627.     CrossRef
  • Impact of the 2024 medical-policy conflict on hepatocellular carcinoma management in Korea
    Soon Sun Kim, Hyun Yang, Jieun Kwon, Eunju Kim, Jeong Il Yu, Janghan Jung, Woosun Choi, Ji Eun Han, Moon Haeng Hur, Bo Hyun Kim, Sung Hyun Kim, Jeong Han Kim, Haeryoung Kim, Pyoung-Jae Park, Hyun Phil Shin, Su Jong Yu, Ki Tae Yoon, Sang Min Yoon, Minjong
    Journal of Liver Cancer.2025; 25(2): 169.     CrossRef
  • Effectiveness of Nursing Care Intervention Among Patients With Hepatocellular Carcinoma Undergoing Surgery: A Systematic Review and Meta‐Analysis
    Wei Geng, Danling Wang, Xinwei Feng
    International Journal of Nursing Practice.2025;[Epub]     CrossRef
  • Current status and future perspectives of minimally invasive liver surgery for hepatocellular carcinoma
    Jai Young Cho, Ho-Seong Han, Yoo-Seok Yoon, Hae Won Lee, Boram Lee, Yeshong Park, Hyelim Joo, Seung Yeon Lim
    Journal of Liver Cancer.2025; 25(2): 233.     CrossRef
  • First-in-India experience with 90Y-BhabhaSphere: an indigenous 90Y-TheraSphere biosimilar for transarterial radioembolization of hepatic malignancies
    Ashish Kumar Jha, Ameya D Puranik, Kunal Bharat Gala, K V Vimalnath Nair, Ardhi Rajeswari, Sharad P Lohar, Aaditya Shah, Amala M Mathai, Bikash K Tiwary, Nitin Sudhakar Shettye, Anupam Mathur, Usha Pandey, Sudipta Chakraborty, Nilendu Purandare, Suyash Ku
    British Journal of Radiology.2025; 98(1176): 2135.     CrossRef
  • CTRP6 in Cancer: Mechanistic Insights and Therapeutic Potential
    Muhammad Zubair Mehboob, Xia Lei
    Cancers.2025; 17(21): 3409.     CrossRef
  • Asian Conference on Tumor Ablation Guidelines for Hepatocellular Carcinoma
    Shuichiro Shiina, Ryosuke Tateishi, Joon Il Choi, So Yeon Kim, Zhiqiang Meng, Lujun Shen, Sheng-Nan Lu, Jen-I. Hwang, Maki Tobari, Hitoshi Maruyama, Terguunbileg Batsaikhan, Qing Deng, Lariza Marie Canseco, Yoshinari Asaoka, Shi-Ming Lin, Kai-Wen Huang, H
    Liver Cancer.2025; 14(5): 651.     CrossRef
  • Applying quality indicators and multidisciplinary team care to improve long-term survival in early-stage hepatocellular carcinoma
    Hui-Ling Huang, Kuan-Chen Pan, Te-Sheng Chang, Shu-Chen Chen, Hsing-Ju Lu, Sheng-Nan Lu
    Asia-Pacific Journal of Oncology Nursing.2025; 12: 100804.     CrossRef
  • Overview of the multidisciplinary team activity in patients with hepatocellular carcinoma and their survival outcomes
    V. Guarini, C. Garzòn, D. Casado, M. Casanova, P. Villarejo, I. Azinovic, E. Crespo, I. Fernandez, M. Lopez, M.M. de Bourio, M. Moran, M. Jimenez, G. Medrano, V. Castellano, A. Lamarca
    ESMO Gastrointestinal Oncology.2025; 10: 100263.     CrossRef
  • Unusual bilateral lymphadenopathy revealing Hodgkin’s lymphoma: a case report
    Vaishnavi D. Rajurkar, Keshao Hiwale, Sahitya Vodithala, Nisha D. Barole, Prajakta Nimbalkar
    Discover Oncology.2025;[Epub]     CrossRef
  • Exploring the role of liver resection as a first-line treatment option for multinodular BCLC-A hepatocellular carcinoma
    Joo Hyun Oh, Dong Hyun Sinn
    Journal of Liver Cancer.2024; 24(2): 126.     CrossRef
  • Comparative Effectiveness of Endoscopic Versus Pharmacological Interventions for Variceal Rebleeding in Cirrhosis: A Systematic Review
    Muath M Dabas, Muhammad Maqbool, Adees W Bedros, Hiba Mazhar, Papuna Papuashvili, Muhammad Umar, Aqsa B Bajwa, Dhruvi H Patel, Nada B Abushalha, Abid Khattak, Junaid Ahmed, Asma Mehdi
    Cureus.2024;[Epub]     CrossRef
  • APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024
    George Lau, Shuntaro Obi, Jian Zhou, Ryosuke Tateishi, Shukui Qin, Haitao Zhao, Motoyuki Otsuka, Sadahisa Ogasawara, Jacob George, Pierce K. H. Chow, Jianqiang Cai, Shuichiro Shiina, Naoya Kato, Osamu Yokosuka, Kyoko Oura, Thomas Yau, Stephen L. Chan, Min
    Hepatology International.2024; 18(6): 1661.     CrossRef
  • Modern Management of Common Bile Duct Stones: Breakthroughs, Challenges, and Future Perspectives
    Yanguang Sha, Zhilin Wang, Rongmei Tang, Ke Wang, Chen Xu, Guangbin Chen
    Cureus.2024;[Epub]     CrossRef
Close layer
Advancing Korean nationwide registry for hepatocellular carcinoma: a systematic sampling approach utilizing the Korea Central Cancer Registry database
Bo Hyun Kim, E Hwa Yun, Jeong-Hoon Lee, Geun Hong, Jun Yong Park, Ju Hyun Shim, Eunyang Kim, Hyun-Joo Kong, Kyu-Won Jung, Young-Suk Lim
J Liver Cancer. 2024;24(1):57-61.   Published online March 26, 2024
DOI: https://doi.org/10.17998/jlc.2024.03.03
  • 10,548 Views
  • 125 Downloads
  • 14 Web of Science
  • 15 Citations
AbstractAbstract PDFSupplementary Material
Hepatocellular carcinoma (HCC) presents a substantial public health challenge in South Korea as evidenced by 10,565 new cases annually (incidence rate of 30 per 100,000 individuals), in 2020. Cancer registries play a crucial role in gathering data on incidence, disease attributes, etiology, treatment modalities, outcomes, and informing health policies. The effectiveness of a registry depends on the completeness and accuracy of data. Established in 1999 by the Ministry of Health and Welfare, the Korea Central Cancer Registry (KCCR) is a comprehensive, legally mandated, nationwide registry that captures nearly all incidence and survival data for major cancers, including HCC, in Korea. However, detailed information on cancer staging, specific characteristics, and treatments is lacking. To address this gap, the KCCR, in partnership with the Korean Liver Cancer Association (KLCA), has implemented a systematic approach to collect detailed data on HCC since 2010. This involved random sampling of 10-15% of all new HCC cases diagnosed since 2003. The registry process encompassed four stages: random case selection, meticulous data extraction by trained personnel, expert validation, anonymization of personal data, and data dissemination for research purposes. This random sampling strategy mitigates the biases associated with voluntary reporting and aligns with stringent privacy regulations. This innovative approach positions the KCCR and KLCA as foundations for advancing cancer control and shaping health policies in South Korea.

Citations

Citations to this article as recorded by  
  • Evaluating the clinical utility of large language models for hepatocellular carcinoma treatment recommendations: A nationwide retrospective registry study
    Keungmo Yang, Jaejun Lee, Jeong Won Jang, Pil Soo Sung, Ji Won Han, Amit Singal
    PLOS Medicine.2026; 23(1): e1004855.     CrossRef
  • Low Tumor Burden Predicts Benefit from Transarterial Treatment in Hepatocellular Carcinoma with Extrahepatic Metastasis: A Nationwide Cohort Study
    Jaejun Lee, Hyun Yang, Keungmo Yang, Ji Won Han, Pil Soo Sung, Jeong Won Jang, Si Hyun Bae
    Liver Cancer.2026; : 1.     CrossRef
  • Discrepancy Between Eligibility and Practice: A 14-Year Nationwide Study on Curative Resection in Elderly Hepatocellular Carcinoma Patients
    Sun Woong Kim, Jun Sik Yoon, Young Lee, Heejoon Jang
    Cancers.2026; 18(15): 2457.     CrossRef
  • Risk of HCC in Elderly Patients With MASLD: Proposal of an Effective Surveillance Strategy
    Young Eun Chon, Kyung‐Do Han, Ju Dong Yang, Ju‐Yeong Park, Hyun‐Seok Kim, Hyung Woong Lee, Tae Seop Lim, Beom Kyung Kim
    Journal of Gastroenterology and Hepatology.2026; 41(9): 2913.     CrossRef
  • Differential Cancer Risks and Noninvasive Predictors in MASLD, MetALD, and ALD: A Longitudinal Analysis
    Hana Park, Ji Young Lee, Ja Eun Koo, Jong Soo Lee, Sungwon Park, Hye Won Park, Hye-Sook Chang, Hong-Kyu Kim, Jaewon Choe, Ju Hyun Shim
    Gut and Liver.2026; 20(5): 880.     CrossRef
  • From practical consensus to clinical integration: positioning stereotactic body radiation therapy in the contemporary management of hepatocellular carcinoma
    Nalee Kim
    Journal of Liver Cancer.2026; 26(2): 179.     CrossRef
  • Self-testing strategy to eliminate hepatitis C as per World Health Organization’s goal: Analysis of disease burden and cost-effectiveness
    Gyeongseon Shin, Beom Kyung Kim, SeungJin Bae, Hankil Lee, Sang Hoon Ahn
    Clinical and Molecular Hepatology.2025; 31(1): 166.     CrossRef
  • Cytokine-Induced Killer Cell Immunotherapy Reduces Recurrence in Patients with Early-Stage Hepatocellular Carcinoma
    Dong Hyun Kim, Eun Min Kim, Jae Seung Lee, Mi Na Kim, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Gi Hong Choi, Sang Hoon Ahn, Hye Won Lee, Do Young Kim
    Cancers.2025; 17(4): 566.     CrossRef
  • Current Trends and Impact of Liver Biopsy on Survival in Hepatocellular Carcinoma: A Korean Multicenter Analysis
    Seong Joon Chun, Jeong-Ju Yoo, Sang Gyune Kim, Young-Seok Kim
    Diagnostics.2025; 15(7): 818.     CrossRef
  • Hepatocellular carcinoma in Korea: an analysis of the 2016-2018 Korean Nationwide Cancer Registry
    Jihyun An, Young Chang, Gwang Hyeon Choi, Won Sohn, Jeong Eun Song, Hyunjae Shin, Jae Hyun Yoon, Jun Sik Yoon, Hye Young Jang, Eun Ju Cho, Ji Won Han, Suk Kyun Hong, Ju-Yeon Cho, Kyu-Won Jung, Eun Hye Park, Eunyang Kim, Bo Hyun Kim
    Journal of Liver Cancer.2025; 25(1): 109.     CrossRef
  • Current status and future perspectives of minimally invasive liver surgery for hepatocellular carcinoma
    Jai Young Cho, Ho-Seong Han, Yoo-Seok Yoon, Hae Won Lee, Boram Lee, Yeshong Park, Hyelim Joo, Seung Yeon Lim
    Journal of Liver Cancer.2025; 25(2): 233.     CrossRef
  • Cellular expansion of hepatocellular carcinoma organoids using decellularized liver scaffolds
    Shin Hwang, I-Ji Jung, Kyoung-Jin Lee, Yun-Kyu Kim, Eunyoung Tak
    Clinical Transplantation and Research.2025; 39(4): 366.     CrossRef
  • Association of modifiable metabolic risk factors and lifestyle with all-cause mortality in patients with hepatocellular carcinoma
    Hwi Young Kim, Hye Ah Lee, Pompilia Radu, Jean-François Dufour
    Scientific Reports.2024;[Epub]     CrossRef
  • Heavy smoking increases early mortality risk in patients with hepatocellular carcinoma after curative treatment
    Jaejun Lee, Jong Young Choi, Soon Kyu Lee
    Journal of Liver Cancer.2024; 24(2): 253.     CrossRef
  • Incorporating ALBI Grade with Geriatric Nutritional Risk Index Enhances Hepatocellular Carcinoma Risk Stratification
    Heechul Nam, Pil Soo Sung, Sung Won Lee, Do Seon Song, Jung Hyun Kwon, Jeong Won Jang, Chang Wook Kim, Si Hyun Bae
    Liver Cancer.2024; : 1.     CrossRef
Close layer
Changing etiology and epidemiology of hepatocellular carcinoma: Asia and worldwide
Do Young Kim
J Liver Cancer. 2024;24(1):62-70.   Published online March 25, 2024
DOI: https://doi.org/10.17998/jlc.2024.03.13
  • 55,588 Views
  • 1,282 Downloads
  • 167 Web of Science
  • 167 Citations
AbstractAbstract PDF
Approximately 80% of hepatocellular carcinoma (HCC) cases arise in sub-Saharan Africa and Eastern Asia, following a similarly high prevalence of chronic hepatitis B virus (HBV) carriers in these regions. The etiology and epidemiology of HCC have recently changed worldwide. Although HBV infection is the main contributor to HCC development, a slow but continuous decline in HBV infection rates has been reported since 1990. Owing to the widespread use of direct-acting antivirals, the incidence of hepatitis C virus-related HCC has remarkably decreased in Japan and European countries. In Korea, Taiwan, and Singapore, the incidence of HBV-related HCC has significantly decreased owing to vaccination against HBV. Globally, while HBV accounted for more than half of HCCs in 1990, this had decreased to 42% in 2019. In contrast, the proportion of patients with alcoholic- and nonalcoholic steatohepatitis (NASH) increased from 13% to 18% and from 5% to 6%, respectively. NASH-related HCC has characteristics that differ from those of virus-associated HCC. Compared with other etiologies, patients with NASHassociated HCC are older, have a higher body mass index, and have higher rates of type 2 diabetes mellitus, hypertension, hyperlipidemia, and cardiovascular disease. Nonalcoholic fatty liver disease (NAFLD)-associated HCC is also known to develop in the absence of cirrhosis, unlike alcohol-related and autoimmune liver diseases. Because patients with NAFLD usually have diabetes or obesity, surveying this population is challenging. Optimal selection of the target population and surveillance tools among patients with NAFLD needs to be determined.

Citations

Citations to this article as recorded by  
  • Therapeutic Potential of Melatonin in Gastrointestinal Cancers: Molecular Mechanisms, Preclinical Evidence and Clinical Implications
    Maciej Gonciarz, Benita Wiatrak, Iga Lombard, Łukasz Konecki, Joanna Sarbinowska
    Journal of Pineal Research.2026;[Epub]     CrossRef
  • Functional imaging: a game changer for biomarker discovery and treatment response among patients with hepatocellular carcinoma
    Shadi Afyouni, Ghazal Zandieh, Timothy M. Pawlik, Ihab R. Kamel
    Expert Review of Gastroenterology & Hepatology.2026; 20(1): 29.     CrossRef
  • Similar hepatic outcome by SGLT2i vs. DPP4i for at-risk cohort with CHB & T2DM: A nationwide target trial emulation study
    Byungyoon Yun, Juyeon Oh, Heejoo Park, Jian Lee, Beom Kyung Kim, Jin-Ha Yoon
    Annals of Hepatology.2026; 31(1): 102175.     CrossRef
  • Efficacy and Safety of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
    Muhammad A.B. Naeem, Muhammad R. Paracha, Ahmad Noor, Muhammad H.A. Khalid, Hafiza K. Shahid, Maaz Khan, Moeaza R. Rizvi, Javeeria Arshad, Talha Abbas, Azeem Saeed, Hamza Ashraf, Minahil Ali, Mishal Asif, Aanusha Ghouri
    American Journal of Clinical Oncology.2026; 49(4): 196.     CrossRef
  • Risk stratification for hepatocellular carcinoma in metabolic dysfunction-associated steatotic liver disease: Editorial on “High Steatosis-Associated Fibrosis Estimator scores predict hepatocellular carcinoma in viral and non-viral hepatitis and metabolic
    Ho Soo Chun, Minjong Lee
    Clinical and Molecular Hepatology.2026; 32(1): 368.     CrossRef
  • BANTAM-01: A Multicenter, Open-Label, First-in-Human Phase 1 Dose Escalation and Expansion Study of 225Ac-GPC3 (BAY 3547926) in Patients with Advanced Hepatocellular Carcinoma
    Jorrit Tjeertes, Miroslav Dostalek, Charles Glaus, Vinita Gupta, Daneng Li, Antje Nestler, Vasiliki Pelekanou, Joerg Pinkert, Ida Ratih, Eric Smith, Shyamal Subramanyam, Arndt Vogel, Katrina Walker, Andrea Wilson Woods, Stefan Zimmermann, Henrik Junger
    Journal of Nuclear Medicine.2026; 67(3): 360.     CrossRef
  • Gut microbiota's role in NAFLD- and HBV/HCV-related hepatocellular carcinoma: Mechanisms and therapeutic implications
    Gursimran Singh, Shazia Ansari, Satyam Yadav, Khadga Raj Aran
    Microbial Pathogenesis.2026; 211: 108273.     CrossRef
  • The Influence of Metabolic Dysfunction-Associated Steatotic Liver Disease and Body Mass Index on the Incidence of Alzheimer Disease: A Nationwide Cohort Study
    Tae Seop Lim, Seok Jong Chung, Jimin Jeon, Ja Kyung Kim, Jinkwon Kim
    Gut and Liver.2026; 20(1): 107.     CrossRef
  • Efficient sustainable nanocarrier based on graphene oxide functionalized with antitumor methotrexate for cancer therapy
    Mohamed Shemis, Hesham Moustafa, Fatma H Salman, Gehan Safwat, Mona Moharib, Samah Mamdouh
    Next Research.2026; 5: 101368.     CrossRef
  • Nuclear miR-3920 expression in hepatocellular carcinoma is associated with stemness marker expression and poorer prognosis
    Hyunjin Park, Seunghye Kim, Hyejung Lee, Hee Young Na, Jeong Eun Yoo, Haeryoung Kim
    Digestive and Liver Disease.2026; 58(3): 390.     CrossRef
  • Matrix Metalloproteinases in Hepatocellular Carcinoma: Mechanistic Roles and Emerging Inhibitory Strategies for Therapeutic Intervention
    Alexandra M. Dimesa, Mathew A. Coban, Alireza Shoari
    Cancers.2026; 18(2): 288.     CrossRef
  • Protein tyrosine phosphatase 1B in solid tumors: Unraveling its clinical significance
    José Esparza-López, Alejandro Aranda-Gutierrez, Elizabeth Escobar-Arriaga, Citlali Frayde-Aguilar, M. Andrea Mac Donald Jamarillo, Eucario Leon-Rodriguez, María de Jesús Ibarra-Sánchez
    Revista de Investigación Clínica.2026; 78(1): 100035.     CrossRef
  • Comprehensive Evaluation and Validation Reveal Mitochondrial Solute Carrier SLC25A3 as a Novel Prognostic Biomarker and Therapeutic Target in Hepatocellular Carcinoma
    Beibei Bie, Libing Liu, Furong Wang, Xianing Meng, Mengdi Wu, Jin Sun
    Journal of Hepatocellular Carcinoma.2026; Volume 13: 1.     CrossRef
  • Antioxidant and Molecular Insights into the Anticancer Potential of Argemone Mexicana L. Seed Extract on HepG2 Cell Line
    Aishwarya R. Kurdekar, A. M. Krupanidhi, S. M. Pratiksha, Prakash Dabadi
    Cell and Tissue Biology.2026; 20(2): 113.     CrossRef
  • Knowledge on modes of hepatitis B transmission and the practice of family screening and vaccination among patients with chronic hepatitis B infection at a tertiary center in Ethiopia
    Sewale Anagaw, Hailemichael Desalegn, Arsema Goytom, Henok Fisseha, Kinfe Woldu, Bizatu Mengistie
    BMC Gastroenterology.2026;[Epub]     CrossRef
  • Exploring the Role of Extracellular Vesicles in Pancreatic and Hepatobiliary Cancers: Advances Through Artificial Intelligence
    Eleni Myrto Trifylli, Athanasios Angelakis, Sotirios P. Fortis, Anastasios G. Kriebardis, Nikolaos Papadopoulos, Evangelos Koustas, Panagiotis Sarantis, Michalis V. Karamouzis, Spilios Manolakopoulos, Melanie Deutsch
    International Journal of Molecular Sciences.2026; 27(3): 1524.     CrossRef
  • Temporal trends and regional variations in hepatocellular carcinoma etiology: a multinational study across Asia
    Yasuto Takeuchi, Ryosuke Tateishi, Shuntaro Obi, Motoyuki Otsuka, Hitoshi Mochizuki, Amarsanaa Jazag, Osamu Yokosuka, Sadahisa Ogasawara, Naoya Kanogawa, Erdenebayar Gonchig, Yuki Matsushita, Murat Kekilli, Gulden Bilican, Yoon Jun Kim, Moon Haeng Hur, Mi
    Hepatology International.2026; 20(2): 373.     CrossRef
  • E-cigarette switching, smoking cessation, and the risk of hepatocellular carcinoma in patients with chronic hepatitis B: A nationwide cohort study in South Korea
    Byeong Geun Song, Myeongcheol Lee, Juhee Cho, Geum-Youn Gwak, Danbee Kang, Dong Hyun Sinn
    Preventive Medicine.2026; 205: 108530.     CrossRef
  • H4K5 lactylation - ENO2 loop drives glycolysis and HCC progression
    Masahiro Yamane, Yoshimitsu Akiyama, Shu Shimada, Shuichi Watanabe, Megumi Hatano, Shu Tsukihara, Suguru Miyazawa, Hanako Tamura, Atsushi Nara, Keita Kodera, Kohei Okazaki, Yoshiaki Tanji, Yosuke Igarashi, Atsushi Kamachi, Kentaro Umemura, Koya Yasukawa,
    JHEP Reports.2026; 8(5): 101786.     CrossRef
  • Comparison between mRECIST, EASL, and qEASL methods with AFP as tumor response parameters after local chemotherapy in patients with intermediate hepatocellular carcinoma
    I G. WIJAYA, Nikmatia LATIEF, Rafikah RAUF, Firdaus HAMID, Bachtiar MURTALA, Luthfi PAREWANGI
    Gazzetta Medica Italiana Archivio per le Scienze Mediche.2026;[Epub]     CrossRef
  • Multi-omics biomarker detection in Diethylnitrosamine (DENA) induced hepatocellular carcinoma
    Obaid Afzal, Pavan Goud, Kavita Goyal, Ali Altharawi, Mubarak A. Alamri, Manal A. Alossaimi, Abdulmalik S.A. Altamimi, Surya Nath Pandey
    Clinica Chimica Acta.2026; 587: 120937.     CrossRef
  • Serum biomarkers as personalised medicine for diagnostic and therapeutic approaches of hepatocellular carcinoma
    Muhammad Taher, Muhamad Aqil Ikram Muhamad Asri, Nur Damia Abdul Rahman, Nur Eleisha Zamzuri, Nur Syazwani Mohammad Farizal, Junaidi Khotib, Deny Susanti, Nurul Athirah Hasdan, Muhammad Salahuddin Haris, Rita Rakhmawati
    Journal of the Egyptian National Cancer Institute.2026;[Epub]     CrossRef
  • Response: Reassessing the Use of Nivolumab Plus Ipilimumab After Atezolizumab Plus Bevacizumab in Advanced HCC
    Jung Sun Kim, Thomas Yau, Hong Jae Chon
    Liver International.2026;[Epub]     CrossRef
  • Immunotherapy in hepatocellular carcinoma: translating mechanistic insights into clinical advances
    Saeed Khavari Khorasani, Siavash Boroumandi, Ali Darzi, Mahla Shokouhfar, Pedram Abdali, Pooya Eini, Ahmad Ghorbani Vanan, Nastaran Bahrami
    Clinical and Experimental Medicine.2026;[Epub]     CrossRef
  • Nanotechnology-Enabled Diagnosis and Treatment of Hepatocellular Carcinoma: Theranostics, Combination Regimens, and Translation
    Siyao Wang, Yang Wu, Miao Yuan, Jing Zheng, Chaoran Wang, Jiarong Wang, Yifan Zheng, Qiaoyun Yang, Mengran Xu, Baiqi Wang
    International Journal of Nanomedicine.2026; Volume 21: 1.     CrossRef
  • PNPLA3 I148M is unrelated to HCC occurrence but associates with poorer tumor differentiation in Korean MASLD: a prospective cohort of 562 patients
    Jaejun Lee, Dong Yeop Lee, Jung Hoon Cha, Hee Sun Cho, Keungmo Yang, Hyun Yang, Mi Young Byun, Seok Keun Cho, Seong Wook Yang, Si Hyun Bae, Pil Soo Sung
    Journal of Liver Cancer.2026; 26(1): 147.     CrossRef
  • A Narrative Review of the Therapeutic Effectiveness of Lenvatinib in Comparison With Immunotherapy for the Treatment of Non-Viral Advanced Hepatocellular Carcinoma
    Pankaj Sonone , Sumit Goyal, Nilesh Lokeshwar, Shruti Dharmadhikari, Gaurav Puppalwar, Chintan Khandhedia, Amey Mane, Suyog Mehta
    Cureus.2026;[Epub]     CrossRef
  • Identification of a Calcium-Related Prognostic Signature and Validation of CACNA1B as a Driver of Metastasis in Hepatocellular Carcinoma
    Yanling Chen, Yarong Ma, Guorui Zhao, Jianhao Li, Guizhen Zhang
    Journal of Hepatocellular Carcinoma.2026; Volume 13: 1.     CrossRef
  • Therapeutic Targeting of miR-21 Restores SASH1 and Sensitizes HBV-HCC to Sorafenib
    Kyuyoung Han, Eun-Kyoung Jwa, Suhyeon Ha, Jiye Kim, Ryunjin Lee, Eunkyeong Lee, Seoon Kang, Hye Ok Kim, Hyunhee Kwon, Dong-Hwan Jung, Young-In Yoon, Gi-Won Song, Gil-Chun Park, Tae Won Kim, Jung-Man Namgoon, Shin Hwang, Eunyoung Tak, Sung-Gyu Lee
    Cancers.2026; 18(6): 1038.     CrossRef
  • Phytoconstituents and Molecular Docking of Ethanol Extract of Sargassum aquifolium J. Agardh with Different Apoptosis Proteins Involved in Hepatocellular Carcinoma
    Anak Agung Ayu Putri Permatasari, Putu Angga Wiradana, I Gede Widhiantara, Ni Kadek Yunita Sari, I Made Gde Sudyadnyana Sandhika, Mochammad Aqilah Herdiansyah, Win Darmanto, Novaria Sari Dewi Panjaitan
    Biomedical & Pharmacology Journal.2026; 1(19): 398.     CrossRef
  • Nuclear prostaglandin E synthase 3 promotes hepatocellular carcinoma growth with immunosuppressive macrophage polarization via the SP1/TGF-β axis
    Nianfei Wang, Wei Chen, Shumin Shen, Jian Qi, Shanghu Wang, Rong Wang, Ming Li, Zixiang Chen, Jiangming Chen, Bo Hong, Hongzhi Wang
    Molecular Biomedicine.2026;[Epub]     CrossRef
  • Lenvatinib combined with immune checkpoint inhibitors for unresectable, recurrent, or metastatic hepatocellular carcinoma: a real-world study
    Huifang Kong, Yan Chen, Hong Li, Di Wang, Xiujuan Chang, Zhen Zeng, Wei Zhang
    The Oncologist.2026;[Epub]     CrossRef
  • CXCR4-Targeted Nanotherapeutics: A Promising Approach for Liver Fibrosis and Hepatocellular Carcinoma Management
    Aftab Ullah, Marina Khan, Yibang Zhang, Muhammad Shafiq, Mohsan Ullah, Azar Abbas, Kifayat Ullah, Xu Xiangxiang, Gang Chen, Yong Diao
    International Journal of Nanomedicine.2026; Volume 21: 1.     CrossRef
  • An automated and portable magnetically-controlled microfluidic chip platform with dual detection modes for sensitive AFP quantification
    Peng Zhang, Chenqi Zhang, Min Jia, Yongdong Pan, Shuo Wu, Jianxin Cheng, Lujie Song, Zizhen Ming
    Analytica Chimica Acta.2026; 1408: 345570.     CrossRef
  • Hepatocellular carcinoma risk, net survival and relative survival ratio in a high-income country of the Eastern Mediterranean Region: 2008–2020
    Saeed Akhtar, Shaimaa Almohaid
    BMC Gastroenterology.2026;[Epub]     CrossRef
  • Evaluation of Factors Affecting Alpha Fetoprotein Levels in Patients With Hepatocellular Carcinoma in a Large Multicenter Cohort
    Nicole Shu Ying Tang, Ethan Kai Jun Tham, Nicholas Syn, Ken Liu, Gang Chen, Beom Kyung Kim, Mark Muthiah, Takumi Kawaguchi, Asahiro Morishita, Sung Won Lee, Karn Wijarnpreecha, Hirokazu Takahashi, Daniel Q. Huang
    Journal of Gastroenterology and Hepatology.2026; 41(6): 1883.     CrossRef
  • Targeting the AMPK/ACC pathway with luteolin suppresses de novo lipogenesis and limits tumor burden in a MASH-HCC mouse model
    Gaoxuan Shao, Chenceng Sun, Chenhao Ye, Ying Liu, Jiashu Pan, Yujing Liu, Lu Lu, Lei Wang, Zemin Lin, Fan Yang, Guang Ji, Hanchen Xu
    Life Sciences.2026; 397: 124440.     CrossRef
  • Artificial Intelligence in Oncology: A Comprehensive Cross-Cancer Translational Readiness Analysis Across 18 Malignancies
    Sai Kiran Kuchana, Uday Kumar Repalle, Nikhilesh V. Alahari, Manpreet Kondamuri, Sai Kiran Manduva, Raghu Vamsi Vanguru, Sri Anjali Gorle, Suresh K. Alahari
    Cancers.2026; 18(10): 1543.     CrossRef
  • Five years after IMbrave150 with clinical integration of atezolizumab plus bevacizumab in hepatocellular carcinoma
    Kuan-Chang Lai, San-Chi Chen
    Annals of Hepatology.2026; 31(2): 102237.     CrossRef
  • Rural-Urban Disparities in Hepatocellular Carcinoma Incidence and Mortality
    Haluk Damgacioglu, Gokhan Uygun, Ashish A. Deshmukh, Ahmed O. Kaseb, Anne M. Noonan, Tarik Demir
    JAMA Network Open.2026; 9(5): e2612323.     CrossRef
  • Hepatocellular Carcinoma Over Three Decades: from Screening Evolution to Integrated Therapeutic Strategies
    Ke Huang, Myoung Ok Kim
    Journal of Cancer Prevention.2026; 31(2): 54.     CrossRef
  • Dietary Polyphenols and Selected Nutraceuticals in Hepatocellular Carcinoma: Mechanistic Insights, Translational Evidence, and Clinical Prospects
    Fareeha Arshad, Arshiya Akbar, Raja Chinnappan, Mohammed Imran Khan, Ahmed Yaqinuddin, Itika Arora
    Nutrients.2026; 18(11): 1783.     CrossRef
  • Elevated TMEM45B expression promotes liver cancer progression and is associated with MET signaling activation
    Hongzhuo Shen, Wenying Zheng, Meiqi Li, Lijun Pei, Jie Xie
    Scientific Reports.2026;[Epub]     CrossRef
  • Engineering Selenium–Chitosan Nanoparticles for Enhanced Hepatic Delivery of Sunitinib and Improved In Vitro Anticancer Activity in Hepatocellular Carcinoma Models
    Ahmed S.G. Srag El-Din, Eman Hamza, Ahmed Y. Kira, Sameh Saber, Mona H. Zohny, Ohoud Y. Alshehri, Reham A. Al-Dhelaan, Eslam Osama Mohamed, Heba I. Elagamy
    Pharmaceuticals.2026; 19(6): 898.     CrossRef
  • Hepatic Tumor Rupture Mimicking Hepatocellular Carcinoma: Diagnosis of Metastatic Small Bowel Gastrointestinal Stromal Tumor by Contrast-Enhanced Ultrasound
    Seungwoo Ha, Jeong-Ju Yoo, Susie Chin, Sang Gyune Kim, Young Seok Kim
    Clinical Ultrasound.2026; 11(1): 93.     CrossRef
  • Targeting lactylation in hepatocellular carcinoma: Mechanistic insights and therapeutic opportunities (Review)
    Lianting Chen, Feiqiong Gao, Qianru Mei, Yujie Li, Qun Cai, Xudong Feng
    International Journal of Molecular Medicine.2026; 58(2): 1.     CrossRef
  • Focal Nodular Hyperplasia Mimicking Hepatocellular Carcinoma in Chronic Hepatitis B Represents a Diagnostic Pitfall
    Tom Ryu, Soung Won Jeong, Young Chang, Jae Young Jang
    Clinical Ultrasound.2026; 11(1): 80.     CrossRef
  • Types and spatial distribution of cancer cases registered in a national hospital-based registry in the Lao People’s Democratic Republic from 2010 to 2024
    Champadeng Vongdala, Oraya Sahat, Thitsamay Luangxay, Apisit Chaidee, Kitti Intuyod, Supot Kamsa-ard, Somchai Pinlaor
    BMC Public Health.2026;[Epub]     CrossRef
  • Circulating miR-184 and miR-206 as predictive biomarkers for early recurrence in HBV-related hepatocellular carcinoma: a prospective study
    Sang-Hoon Kim, Ryunjin Lee, Eunyoung Tak, Ki-Hun Kim
    BMC Gastroenterology.2026;[Epub]     CrossRef
  • Safranal improves the anticancer efficacy of sorafenib via transcriptomic reprogramming and metabolomic changes in a rat model of diethylnitrosamine-induced cirrhosis–hepatocellular carcinoma
    Ameera Al Mansoori, Badriya Baig, Rania Harati, Reem Sami Alhamidi, Alaaeldin A. Hamza, Suhail Al-Salam, Anne Le, Cissy Zhang, Pratik Khare, Rifat Hamoudi, Amr Amin
    Naunyn-Schmiedeberg's Archives of Pharmacology.2026; 399(12): 19597.     CrossRef
  • Neoadjuvant Immunotherapy for Hepatocellular Carcinoma Is Associated with Improved Survival After Hepatectomy: A Matched Analysis of the 2017 to 2022 National Cancer Database
    Lawrence Chiang, Adam Bodzin, Daniel Lin, Nader Hanna, Scott Koeneman, Hien Dang, Charles J. Yeo, Christopher Shubert, Richard Zheng
    Cancers.2026; 18(13): 2137.     CrossRef
  • Plasma interleukin-8 as a predictive biomarker for tyrosine kinase inhibitor response in advanced hepatocellular carcinoma
    Sujin Kim, Hye Ri Ahn, Hui Gyeong Kim, Dooyeon Kim, Ji Eun Han, Soon Sun Kim, Jae Youn Cheong, Jung Woo Eun, Hyo Jung Cho
    Discover Oncology.2026;[Epub]     CrossRef
  • External Beam Radiation Therapy and Immunotherapy in the Management of Hepatobiliary Malignancies: A Meta-analysis of Treatment Response Rates
    Juan Jose Juarez Vignon Whaley, Mary Linton Peters, Matthew J. Abrams
    International Journal of Radiation Oncology*Biology*Physics.2026; 126(3): 715.     CrossRef
  • PER1 reduces HIF-1α nuclear accumulation and modulates vascular remodeling in hepatocellular carcinoma
    Zhen Zhang, Caihong Ning, Si Mei, Chun Yi, Heyun Tao, Linzhu Lu, Sian Pan, Zhiqi Wang, Xuefei Tian
    Molecular and Cellular Biochemistry.2026; 481(8): 3715.     CrossRef
  • Urinary Gas Chromatography‐Based Metabolomics for Early Detection of Liver Cirrhosis and Hepatocellular Carcinoma: A Decade of Progress
    Diaa I. Osman, Sheta M. Sheta, Mostafa I. Abdelglil, Fatma O. Khalil, Waheed M. Salem, Naser A. Naser, Ahmed Attia
    Biomedical Chromatography.2026;[Epub]     CrossRef
  • A novel bivalent neoantigen vaccine based on mRNA-loaded lipid nanoparticles eradicates hepatocellular carcinoma in mice
    Mahmoud A. Younis, Yusuke Sato, Yaser H.A. Elewa, Hideyoshi Harashima
    Journal of Controlled Release.2026; 397: 115172.     CrossRef
  • Metabolic Dysfunction-Associated Fibrosis 5 Score and the Risk of Liver-Related Events in the General Population
    Byeong Geun Song, Goeun Park, Myung Ji Goh, Wonseok Kang, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Dong Hyun Sinn
    Gut and Liver.2026; 20(4): 645.     CrossRef
  • Efficacy and Long-Term Outcomes of Direct-Acting Antivirals in Patients with Hepatitis C Virus-Related Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
    Jeong-Ju Yoo, Seul Ki Han, Soon Sun Kim, Hyun Yang, Eunju Kim, Seong Hee Kang, Young Eun Chon, Eileen L. Yoon, Hyun Phil Shin, Sangheun Lee, Do Young Kim, Gi Hyeon Seo, Hyung Joon Kim, Hyun Woong Lee
    Gut and Liver.2026; 20(4): 665.     CrossRef
  • A scheme to tackle the dilemma from hepatoma cells under doxorubicin-resistant surroundings: a brightness or a silhouette
    Ki-Kwang Oh, Goo-Hyun Kwon, Jung-A Eom, Kyeong Jin Lee, Dong Joon Kim, Ki-Tae Suk
    Artificial Cells, Nanomedicine, and Biotechnology.2026; 54(1): 374.     CrossRef
  • Detection of serum levels of human telomerase reverse transcriptase mRNA in non-alcoholic steatohepatitis related hepatocellular carcinoma in Sri Lanka
    Usman Umar Liman, Asanka Sudeshini Hewage, Sumadee de Silva, Saumya Madushani Samarasinghe, Kamani Hemamala Tennekoon, Rohan Chaminda Siriwardana, Madunil Anuk Niriella
    South Asian Journal of Cancer.2026; 15: 362.     CrossRef
  • Risk Prediction of Early‐Onset Hepatocellular Carcinoma: Derivation and Validation in a Nationwide Young Adult Cohort
    Seogsong Jeong, Gi‐Ae Kim, Heejoon Jang, Dong Hyeon Lee, Sae Kyung Joo, Keon Wook Kang, Hwamin Lee, Won Kim
    Alimentary Pharmacology & Therapeutics.2026; 64(4): 507.     CrossRef
  • Efficacy and safety of transarterial chemoembolization combined with donafenib and camrelizumab for hepatocellular carcinoma with portal vein tumor thrombus: a dual-center, retrospective propensity score-matched analysis
    Qi Zhang, Hezi Qing, Zhenwu Lei, Xingwu Xie
    Frontiers in Immunology.2026;[Epub]     CrossRef
  • The impact of alcohol consumption on the risk of hepatocellular carcinoma across different age groups: A nationwide cohort study
    Mi Na Kim, Kyungdo Han, Dong Yun Kim, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Sang Hoon Ahn, Do Young Kim
    JHEP Reports.2026; 8(10): 101975.     CrossRef
  • Risk-stratified MRI surveillance for hepatocellular carcinoma in cirrhosis: a prospective cohort study
    Byeong Geun Song, Woo Kyoung Jeong, Myung Ji Goh, Wonseok Kang, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Dong Hyun Sinn
    European Radiology.2026;[Epub]     CrossRef
  • Socioeconomic Factors Impacting Survival in Patients With Hepatocellular Carcinoma Treated With Locoregional Therapies: A Single-Center Study
    Mariam Dogar, Zohaa Faiz, Muhammad Mohid Tahir, Aamir Ali, Razan Ali, Victor Novack, Mary Linton B. Peters, Andrea Bullock, Michael Curry, Diana Dinh, Jeffrey Weinstein, Muneeb Ahmed, Ammar Sarwar
    Journal of Vascular and Interventional Radiology.2026; 37(10): 108937.     CrossRef
  • Plasma cell-CD8+ T cell co-enrichment distinguishes immunotherapy-responsive hepatocellular carcinoma subtypes
    Aryan Neupane, Anuradha Budhu, Farid Rashidi Mehrabadi, Aiwu He, Lipika Goyal, Robin Kate Kelley, Tim F Greten, Xin Wei Wang
    eGastroenterology.2026; 4(3): e100423.     CrossRef
  • GRP78/BiP as a novel midbody component induces mitotic exit failure via PLK1 stabilization in hepatocellular carcinoma
    Sanghwa Kim, Yeonhwa Song, Su-Yeon Lee, Kang mo Kim, Haeng Ran Seo
    BMB Reports.2026; 59(8): 398.     CrossRef
  • Environmental factors related to pathogenesis of hepatocellular carcinoma
    Li-Baihe Jing, Yu-Min Li
    Hepatobiliary & Pancreatic Diseases International.2026; 25(5): 476.     CrossRef
  • Shear wave elastography demonstrates similar risk stratification performance to vibration-controlled transient elastography in FIB-4–based two-step algorithms for MASLD
    Jaejun Lee, Hyun Yang, Si Hyun Bae, Sunhong Yoo, Soon Woo Nam, Jiwoon Yoon, Jung Hyun Kwon, Soon Kyu Lee
    Hepatology.2026;[Epub]     CrossRef
  • Integrative predictive modelling and multi-omics validation reveals potential indicators of clinical heterogeneity in HCC
    Rashi Jain, Veena Puri, Sathish Kumar Mungamuri, Prabha Garg
    Biochemical and Biophysical Research Communications.2026; 837: 154590.     CrossRef
  • Antiviral therapy and hidden predictors of postoperative outcomes in hepatocellular carcinoma
    Nadeem Ashraf, Qingyong Hong, Zhidong Guo, Kun Li
    BMC Cancer.2026;[Epub]     CrossRef
  • The role of mitochondrial DNA and RNA in promoting liver disease pathogenesis
    Sanjeevani Raj, Anjali Warhade, Nikkee Kumari, Shweta Pandey, Mrigya Babuta
    Frontiers in Cell and Developmental Biology.2026;[Epub]     CrossRef
  • Cell-free DNA methylation markers in the diagnosis of hepatitis B virus-related- hepatocellular carcinoma: a review
    Serge Theophile Soubeiga, Abdoul Karim Ouattara, Corine Ilboudo, Wendkuuni Florencia Djigma, Jacques Simpore
    Molecular Biology Reports.2026;[Epub]     CrossRef
  • Alterations of Nutrient Elements in Hepatocellular Carcinoma Patients Treated with Atezolizumab-Bevacizumab
    Shuyue Xiao, Xiaohui Huang, Shuer Liu, Di Jin, Zheng Liu
    Nutrition and Cancer.2025; 77(2): 244.     CrossRef
  • Structure–activity relationship studies of Imidazo[1′,2′:1,6]pyrido[2,3-d]pyrimidine derivatives to develop selective FGFR inhibitors as anticancer agents for FGF19-overexpressed hepatocellular carcinoma
    Jisook Kim, Seung Hyun Jung, Joo Chan Lee, Won Jeoung Kim, Jooyun Byun, Young Gil Ahn, Hyun-Ju Park
    European Journal of Medicinal Chemistry.2025; 282: 117047.     CrossRef
  • Liver cancer in Saudi Arabia: A registry-based nationwide descriptive epidemiological and survival analysis
    Nawal H. Almohammadi
    Cancer Epidemiology.2025; 94: 102731.     CrossRef
  • Worse survival of hepatocellular cancer patients with membranous insulin receptor overexpression
    Steffen Markus Heckl, Carolin Schneider, Lukas Kercher, Hans-Michael Behrens, Jan-Paul Gundlach, Alexander Bernsmeier, Stephan Schmidt, Sandra Krüger, Felix Braun, Rainer Günther, Thomas Becker, Stefan Schreiber, Christoph Röcken
    Scientific Reports.2025;[Epub]     CrossRef
  • Therapeutic Effects of Crocin Nanoparticles Alone or in Combination with Doxorubicin against Hepatocellular Carcinoma In vitro
    Noha S. Basuony, Tarek M. Mohamed, Doha M. Beltagy, Ahmed A. Massoud, Mona M. Elwan
    Anti-Cancer Agents in Medicinal Chemistry.2025; 25(3): 194.     CrossRef
  • Structural insights into antibody-based immunotherapy for hepatocellular carcinoma
    Masaud Shah, Muhammad Hussain, Hyun Goo Woo
    Genomics & Informatics.2025;[Epub]     CrossRef
  • Self-testing strategy to eliminate hepatitis C as per World Health Organization’s goal: Analysis of disease burden and cost-effectiveness
    Gyeongseon Shin, Beom Kyung Kim, SeungJin Bae, Hankil Lee, Sang Hoon Ahn
    Clinical and Molecular Hepatology.2025; 31(1): 166.     CrossRef
  • Tenofovir Disoproxil Fumarate Versus Entecavir: Effects on Lipid Profiles and Cardiovascular Outcomes in People Living With Chronic Hepatitis B
    Log Young Kim, Jae Young Kim, Jeong‐Ju Yoo, Sang Gyune Kim, Young‐Seok Kim
    Journal of Medical Virology.2025;[Epub]     CrossRef
  • Cytokine-Induced Killer Cell Immunotherapy Reduces Recurrence in Patients with Early-Stage Hepatocellular Carcinoma
    Dong Hyun Kim, Eun Min Kim, Jae Seung Lee, Mi Na Kim, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Gi Hong Choi, Sang Hoon Ahn, Hye Won Lee, Do Young Kim
    Cancers.2025; 17(4): 566.     CrossRef
  • Comparison of hepatocellular carcinoma incidence after long-term treatment with besifovir vs. tenofovir AF
    Hyuk Kim, Jae-Young Kim, Yoon E. Shin, Hye-Jin Yoo, Jeong-Ju Yoo, Sang Gyune Kim, Young-Seok Kim
    Scientific Reports.2025;[Epub]     CrossRef
  • Targeting metabolic diseases with celastrol: A comprehensive review of anti-inflammatory mechanisms and therapeutic potential
    Xiaojuan Wang, Mohamad Hafizi Abu Bakar, Song Liqun, Mohd Asyraf Kassim, Khairul Anuar Shariff, Thiruventhan Karunakaran
    Journal of Ethnopharmacology.2025; 344: 119560.     CrossRef
  • Advancements in autoimmune hepatitis epidemiology, treatment and complication – a 15-year retrospective study
    Mifleh Tatour, Fadi Abu Baker, Tarek Saadi, Ahmad Yahia, Rawi Hazzan
    Clinics and Research in Hepatology and Gastroenterology.2025; 49(4): 102570.     CrossRef
  • Metabolic Cause of Cirrhosis Is the Emerging Etiology for Primary Liver Cancer in the Asia‐Oceania Region: Analysis of Global Burden of Disease (GBD) Study 2021
    Suprabhat Giri, Sushrut Ingawale, Gaurav Khatana, Prasanna Gore, Dibya Lochan Praharaj, Vincent Wai‐Sun Wong, Daniel Q. Huang, Amit Singhal, Ashok Choudhury
    Journal of Gastroenterology and Hepatology.2025; 40(5): 1188.     CrossRef
  • Role of hepatotropic viruses in promoting hepatocellular carcinoma—current knowledge and recent advances
    Piotr Starnawski, Klaudia Nowak, Zuzanna Augustyn, Dominik Malicki, Aleksandra Piąta, Dominika Lorek, Jakub Janczura
    Medical Oncology.2025;[Epub]     CrossRef
  • Investigating the functional role of BUB1B in aflatoxin B1-associated hepatocarcinogenesis
    Hayam Hamdy, Wafaa A. Aly, Eyad Elkord
    Toxicology.2025; 514: 154127.     CrossRef
  • Synergistic effects of L-arginine and argininosuccinate synthetase 1 in inducing apoptosis in hepatocellular carcinoma
    Jin Sun Kim, Won-Mook Choi, Ha-Il Kim, Sung Won Chung, Jonggi Choi, Danbi Lee, Kang Mo Kim
    Journal of Liver Cancer.2025; 25(1): 79.     CrossRef
  • Association between allopurinol and hepatocellular carcinoma: analysis of genetic risk and patient survival
    Yu-fu Li, Hui-wei Wang, Huan-yan Peng, Zhen-ying Zhang, Zhi-jia Yao, Yuan Meng, Dong-ye Yang
    Discover Oncology.2025;[Epub]     CrossRef
  • A Comparative Analysis of the Roles of von Willebrand Factor and ADAMTS13 in Hepatocellular Carcinoma: A Bioinformatics and Microarray-Based Study
    Durmuş Ayan, Şerife Buket Bozkurt Polat, Ergül Bayram, Esma Özmen, Fatma Esin Aydın, Serpil Ersan
    Current Issues in Molecular Biology.2025; 47(4): 270.     CrossRef
  • Hepatitis B virus genotype distribution and mutation patterns: Insights and clinical implications for hepatitis B virus positive patients
    Manisha M Ratnaparkhi, Chanda R Vyawahare, Nageswari R Gandham
    World Journal of Experimental Medicine.2025;[Epub]     CrossRef
  • Reply to correspondence on “Aberrant fragmentomic features of circulating cell-free mitochondrial DNA enable early detection and prognosis prediction of hepatocellular carcinoma”
    Hyuk Soo Eun
    Clinical and Molecular Hepatology.2025; 31(2): e215.     CrossRef
  • Construction of a tumor immune microenvironment-related risk scoring model for prognosis of hepatocellular carcinoma
    Xinyi Li, Zifan Qin, Haozhi Chen, Daichuan Chen, Nafisa Alimu, Duoduo Li, Xiyu Cheng, Qiong Yan, Lishu Zhang, Xingwei Liu, Zitong Zhou, Jiayi Zhu, Hangqi Ma, Xinyue Pei, Hanli Xu, Jiaqiang Huang
    International Journal of Immunopathology and Pharmacology.2025;[Epub]     CrossRef
  • Comparative Hepatic Outcomes of SGLT2i or DPP4i Compared to GLP‐1RA in CHB and T2DM Patients
    Byungyoon Yun, Juyeon Oh, Heejoo Park, Jian Lee, Beom Kyung Kim, Jin‐Ha Yoon
    Liver International.2025;[Epub]     CrossRef
  • Bioinformatics-driven identification of key non-invasive prognostic biomarkers in hepatocellular carcinoma
    Muhammad-Redha Abdullah-Zawawi, Muhammad Irfan Abdul Jalal, Shing Cheng Tan, Loscheni Varma, Nur Alyaa Afifah Md Shahri, Mira Farzana Mohamad Mokhtar, Ryia Illani Mohd Yunos, Nurul Syakima Ab Mutalib, Rahman Jamal
    Egyptian Journal of Medical Human Genetics.2025;[Epub]     CrossRef
  • Marine L-arginase encapsulated in poly (lactic-co-glycolic acid) nanoparticles: A novel anti-cancer strategy for effective hepatocellular carcinoma treatment in vitro and in vivo
    Amria M. Mousa, Mohamed Abdelraof, Amany A. Hassabo, Doaa A. Darwish, Mona M.A. Abdel-Mottaleb, Rasha M. Allam
    Journal of Drug Delivery Science and Technology.2025; 109: 106980.     CrossRef
  • Redefining precision medicine in hepatocellular carcinoma through omics, translational, and AI-based innovations
    Rashi Jain, Sathish Kumar Mungamuri, Prabha Garg
    The Journal of Precision Medicine: Health and Disease.2025; 1: 100003.     CrossRef
  • Myosteatosis and the survival of patients with hepatocellular carcinoma: a meta-analysis
    Yongjuan Wu, Guangyuan Cheng, Jun Han, Qingsong Yang
    Clinical and Experimental Medicine.2025;[Epub]     CrossRef
  • Exploring the antitumor potential of cucurbitacin B in hepatocellular carcinoma through network pharmacology, molecular docking, and molecular dynamics simulations
    Hongyu Zhang, Baixiu Wu, Liuhua Ke, Xiaoyuan Fan, Liji Huang, Zheng Peng
    Naunyn-Schmiedeberg's Archives of Pharmacology.2025; 398(11): 14751.     CrossRef
  • Therapeutic efficacy of canagliflozin against hepatocarcinogenesis induced by CDD/DEN/TAA in a rat model: regulation of AMPK/HIF-1α/YAP-1/TAZ signaling pathways
    Hany M. Fayed, Gihan F. Asaad, Marawan A. Elbaset, Ola A. Sharaf, Sawsan S. Mahmoud, Mohamed M. Amin, Zeinab A. El-Gendy, Fatma A. Ibrahim, Sherein S. Abdelgayed, Rehab F. Abdel-Rahman
    Naunyn-Schmiedeberg's Archives of Pharmacology.2025; 398(11): 16131.     CrossRef
  • The use of artificial intelligence in stereotactic ablative body radiotherapy for hepatocellular carcinoma
    Atsuto Katano
    Frontiers in Medicine.2025;[Epub]     CrossRef
  • Extracellular vesicles as a promising platform of precision medicine in liver cancer
    Keyang Xu, Qibiao Wu, Zhao Lingyun, Romario Nguyen, Fatema Safri, William Yang, Yikun Xu, Yun Ye, Hiu Yee Kwan, Qiang Wang, Xiuming Liang, Muhammad J.A. Shiddiky, Majid E. Warkiani, Jacob George, Liang Qiao, Jianfeng Bao
    Pharmacological Research.2025; 217: 107800.     CrossRef
  • Spinal Cord Infarction After Transarterial Chemoembolization for Hepatocellular Carcinoma: A Case Report
    Tho Tran Dinh, Sy Than Van, Vinh Chu Van, Phuc Chu Minh
    Cureus.2025;[Epub]     CrossRef
  • Association between early job loss and prognosis among hepatocellular carcinoma survivors
    B Yun, J Oh, S H Ahn, B K Kim, J-H Yoon
    Occupational Medicine.2025; 75(2): 113.     CrossRef
  • All-cause and disease-specific mortality in young adults with MASLD: A nationwide cohort study
    Jeayeon Park, Goh Eun Chung, Su Jong Yu, Yoon Jun Kim, Jung-Hwan Yoon, Kyungdo Han, Eun Ju Cho
    JHEP Reports.2025; 7(9): 101477.     CrossRef
  • Low-Abundance Serum Protein Biomarker Candidates for HCC in Patients with Liver Cirrhosis
    Muhammad Salman Sajid, Rency S. Varghese, Alexander Kroemer, Habtom W. Ressom
    Journal of Proteome Research.2025; 24(7): 3656.     CrossRef
  • Roadmap for HCC Surveillance and Management in the Asia Pacific
    Masatoshi Kudo, Bui Thi Oanh, Chien-Jen Chen, Do Thi Ngat, Jacob George, Do Young Kim, Luckxawan Pimsawadi, Pisit Tangkijvanich, Raoh-Fang Pwu, Rosmawati Mohamed, Sakarn Bunnag, Sheng-Nan Lu, Sirintip Kudtiyakarn, Tatsuya Kanto, Teerha Piratvisuth, Chao-C
    Cancers.2025; 17(12): 1928.     CrossRef
  • Computational Repurposing of Approved Drugs: Exploring New Therapeutic Avenues for Liver Disorders
    Pranali Jadhav, Asha Thomas, Somdatta Chaudhari, Sohan Chitlange
    Journal of Pharmaceutical Innovation.2025;[Epub]     CrossRef
  • Antibody treatment of hepatocellular carcinoma: a review of current and emerging approaches
    Sherif A. El-Kafrawy, Mostafa S. Elkafrawy, Esam I. Azhar, Anwaar Saeed, Ashraf A. Tabll
    Frontiers in Immunology.2025;[Epub]     CrossRef
  • Pathogenic effects of telomerase reverse transcriptase (TERT) promoter mutations in nonalcoholic steatohepatitis (NASH) related hepatocellular carcinoma (HCC) and its potentials as a diagnostic biomarker
    Usman Umar Liman, Asanka Sudeshini Hawage, Sumadee De Silva, Saumya Madushani Samarasinghe, Kamani Hemamala Tennekoon, Rohan Chaminda Siriwardana, Madunil Anuk Niriella
    Egyptian Journal of Medical Human Genetics.2025;[Epub]     CrossRef
  • Perspectives on NcRNAs in HBV/cccDNA-driven HCC progression
    Yang-Hsiang Lin, Ming-Wei Lai, Chau-Ting Yeh, Wey-Ran Lin
    Cancer Cell International.2025;[Epub]     CrossRef
  • Burden of liver cancer in the European region from 1990 to 2021: a sub-analysis of the global burden of disease study
    Onika Kazi, Shokoufeh Hamidzadeh, Babak Ehsani Zunuz, Abdolsabour Khordoo, Seyede Saba Mazloomi, Hossein Khademsedaghat, Mohammad Amin Khadembashiri
    Annals of Medicine & Surgery.2025; 87(7): 4053.     CrossRef
  • Systemic treatment of liver cancer: Current status and future perspectives
    Chun-Bo Li, Yu-Ting Ning, Nai-Ying Shen, Ben Wang, Han Xiao, Gang Luo
    World Journal of Hepatology.2025;[Epub]     CrossRef
  • Exploring the Epidemiologic Burden, Pathogenetic Features, and Clinical Outcomes of Primary Liver Cancer in Patients with Type 2 Diabetes Mellitus (T2DM) and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Scoping Review
    Mario Romeo, Fiammetta Di Nardo, Carmine Napolitano, Claudio Basile, Carlo Palma, Paolo Vaia, Marcello Dallio, Alessandro Federico
    Diabetology.2025; 6(8): 79.     CrossRef
  • Rapid Bone Metastasis in Hepatocellular Carcinoma: A Case Report
    Laraib ., Uzma Khalid, Ayesha Khalid
    Cureus.2025;[Epub]     CrossRef
  • Multi-Omics Feature Selection to Identify Biomarkers for Hepatocellular Carcinoma
    Rency S. Varghese, Xinran Zhang, Sarada Giridharan, Muhammad Salman Sajid, Md Mamunur Rashid, Alexander Kroemer, Habtom W. Ressom
    Metabolites.2025; 15(9): 575.     CrossRef
  • The PNPLA3 I148M variant is associated with immune cell infiltration and advanced fibrosis in MASLD: a prospective genotype–phenotype study
    Jaejun Lee, Jung Hoon Cha, Hee Sun Cho, Keungmo Yang, Hyun Yang, Heechul Nam, Mi Young Byun, Seok Keun Cho, Jinsung Park, Hyuk Wan Ko, Seong Wook Yang, Pil Soo Sung, Si Hyun Bae
    Journal of Gastroenterology.2025; 60(10): 1284.     CrossRef
  • Emodin promotes GSK-3β-mediated PD-L1 proteasomal degradation and enhances anti-tumor immunity in hepatocellular carcinoma
    Xuemei Yang, Weiguang Chen, Haitao Sun, Weicong Chen, Wei Xu, Chunyu He, Yang Liu, Ying Kuang, Yanhao Ma, Binglian Zhong, Chaojie Li, Guohuan Li, Qingfeng Du, Songqi He
    Chinese Medicine.2025;[Epub]     CrossRef
  • Direct-acting Antivirals Therapy for Hepatocellular Carcinoma in Hepatitis C Patients
    Seul Ki Han, Soon Koo Baik, Moon Young Kim
    Journal of Digestive Cancer Research.2025; 13(2): 150.     CrossRef
  • Quantum chemical optimization and residue-specific stabilization of CDK20 inhibitors in hepatocellular carcinoma
    Ahmed I. Foudah, Mohammed H. Alqarni, Tariq M. Aljarba, Talha Jawaid, Osama A. Alkhamees, Saud M. Alsanad, Khalid I. AlHussaini, Aftab Alam
    Molecular Diversity.2025; 30(3): 3977.     CrossRef
  • Association between metabolites and hepatocellular carcinoma: findings from a two-sample Mendelian randomization study
    Tung Hoang, Van Mai Truong, Tho Thi Anh Tran, Bao Le Thai Tran, Ngoc Hong Cao
    Journal of Liver Cancer.2025; 25(2): 251.     CrossRef
  • Fig Seed Oil Induces Mitochondrial-Mediated Apoptosis in HepG2 Cells
    Adem Yavaş
    SDÜ Tıp Fakültesi Dergisi.2025; 32(3): 230.     CrossRef
  • Heme Oxygenase-1 Expression as a Prognostic Marker in Early-Stage HCC Undergoing Resection or Liver Transplantation
    Ramona Cadar, Alin Mihai Vasilescu, Ana Maria Trofin, Alexandru Grigorie Nastase, Mihai Zabara, Cristina Muzica, Corina Lupascu Ursulescu, Mihai Danciu, Andrei Pascu, Iulian Buzincu, Delia Ciobanu, Ianole Victor, Cristian Dumitru Lupascu
    Life.2025; 15(10): 1589.     CrossRef
  • Quantification, antioxidant, in-silico molecular docking and anti-hepatocellular carcinoma activity of Sepia ink polysaccharides prepared from Sepia pharaonis
    Sandhanam Kuppusamy, Bedanta Bhattacharjee, Abarnadevika Alagiri, Sumithra Mohan, Ram Kumar Sahu, Abhishek Bhattacharjee, Chitra Vellapandian
    Future Journal of Pharmaceutical Sciences.2025;[Epub]     CrossRef
  • MicroRNA Landscape in Hepatocellular Carcinoma: Metabolic Re-Wiring, Predictive and Diagnostic Biomarkers, and Emerging Therapeutic Targets
    Dimitris Liapopoulos, Panagiotis Sarantis, Theodora Biniari, Thaleia-Eleftheria Bousou, Eleni-Myrto Trifylli, Ioanna A. Anastasiou, Stefania Kokkali, Dimitra Korakaki, Spyridon Pantzios, Evangelos Koustas, Ioannis Elefsiniotis, Michalis V. Karamouzis
    Biomedicines.2025; 13(9): 2243.     CrossRef
  • Current status and future perspectives of minimally invasive liver surgery for hepatocellular carcinoma
    Jai Young Cho, Ho-Seong Han, Yoo-Seok Yoon, Hae Won Lee, Boram Lee, Yeshong Park, Hyelim Joo, Seung Yeon Lim
    Journal of Liver Cancer.2025; 25(2): 233.     CrossRef
  • Navigating liver cancer with mouse models: a comprehensive overview of HCC experimental systems
    Ga-Young Kim, Dokyung Kim, Jaehyun Jeon, Wonhyo Seo, Seol Hee Park
    Journal of Liver Cancer.2025; 25(2): 239.     CrossRef
  • Effects of the Polar Fraction of Lophocereus schottii on Gene Expression and Hepatocyte Proliferation in a Wistar Rat Model of Hepatocellular Carcinoma
    Marina Campos-Valdez, Jaime Sánchez-Meza, Arturo Orozco-Barocio, José A. Domínguez-Rosales, Juliana Marisol Godínez-Rubí, Sarai C. Rodríguez-Reyes, Erika Martínez-López, Miriam R. Bueno-Topete, Manuel A. Castro-García, Guillermo M. Zúñiga-González, Daniel
    International Journal of Molecular Sciences.2025; 26(19): 9788.     CrossRef
  • Radiomic Analysis in Hepatocellular Carcinoma: Prospects and Clinical Benefits (Review)
    E. B. Kodzoeva, K. A. Romanova, B. M. Medvedeva, N. Ts. Drobot
    Journal of oncology: diagnostic radiology and radiotherapy.2025; 8(3): 78.     CrossRef
  • Biodistribution and Radiation Dosimetry of [68Ga]Ga-RAYZ-8009, a Glypican 3–Targeting Compound for Imaging of Hepatocellular Carcinoma
    Oliver Viering, Julia Brosch-Lenz, Ralph A. Bundschuh, Helen Scholtissek, Johanna S. Enke, Adriana Amerein, Georgine Wienand, Alexander Dierks, Malte Kircher, Marianne Patt, Christian H. Pfob, Constantin Lapa
    Journal of Nuclear Medicine.2025; 66(11): 1737.     CrossRef
  • Evaluating the Antitumor Effect of Root Extract of Salvadora persica in Hepatocarcinoma Through the Induction of Apoptosis via an Intrinsic Pathway: An In Vitro Study
    Fouzia Latif, Kong Qun, Mingjing Lu
    Cureus.2025;[Epub]     CrossRef
  • Nationwide analysis of renal outcomes in chronic hepatitis B patients treated with Tenofovir Alafenamide vs. Entecavir
    Hyuk Kim, Jae Young Kim, Hye-Jin Yoo, Log Young Kim, Jeong-Ju Yoo, Sang Gyune Kim, Young-Seok Kim
    Scientific Reports.2025;[Epub]     CrossRef
  • Arachidonic acid induces ferroptosis in hepatocellular carcinoma via the SIRT5-ACSL4/LPCAT3/ALOX15 axis, leading to lipid peroxidation and mitochondrial dysfunction
    Peisen Xue, Jingting Zhang, Zhibing Wang, Ling Wu, Jincheng Tang, Renyi Yang, Wenhui Gao, Puhua Zeng
    Phytomedicine.2025; 148: 157450.     CrossRef
  • Quantitative Ultrasound Assessment of Liver Fat Using Deep Learning and Clinical Data Integration
    Jirakorn Jamrasnarodom, Terapap Apiparakoon, Sanparith Marukatat, Oracha Chaichuen, Sasima Sukchareon, Roongruedee Chaiteerakij
    Journal of Medical and Biological Engineering.2025; 45(6): 817.     CrossRef
  • Racial disparities in hepatocellular carcinoma: a TCGA-based gene expression study of Caucasian and Asian populations
    Muhammad Rezki Rasyak, Sri Jayanti, Cyrollah Disoma, Bens Pardamean, Caecilia Sukowati
    Exploration of Targeted Anti-tumor Therapy.2025;[Epub]     CrossRef
  • Circulating miRNAs combined with AFP improve diagnostic accuracy for HBV-associated hepatocellular carcinoma
    Ngo Dieu Hoa, Dao Phuong Giang, Nguyen Thi Thu Hien, Dang Thi Ngoc Dung, Mai Thanh Binh, Ngo Tat Trung, Tran Thi Thanh Huyen, Hoang Van Tong, Thirumalaisamy P. Velavan, Le Huu Song, Nghiem Xuan Hoan
    Biochemistry and Biophysics Reports.2025; 44: 102343.     CrossRef
  • A contrast‑enhanced CT histogram‑driven nomogram for predicting post‑radiotherapy liver regeneration in hepatocellular carcinoma
    Bo Liu, Yuan Xu, Xijie Zhang, Wei Qi, Bo Ren, Wenjia Kong, Wence Zhou
    Radiation Oncology.2025;[Epub]     CrossRef
  • –A novel peptide SMIM45-107aa promotes HCC progression via MTDH pathways and its anticancer peptide derivative
    Yan An, Xiangyang Shi, Wentao Huang, Mingyi Shang, Guang-Zhi Jin
    Journal of Translational Medicine.2025;[Epub]     CrossRef
  • Advanced Hepatocellular Carcinoma Missed on Ultrasonography: A Case Report
    Tom Ryu, Jae Young Jang, Yon Hee Kim, Young Chang, Soung Won Jeong
    Clinical Ultrasound.2025; 10(2): 114.     CrossRef
  • Personalized Mortality Risk Stratification in ALD- and MASLD-Related Hepatocellular Carcinoma Using a Machine Learning Approach
    Miguel Suárez, Sergio Gil-Rojas, Pablo Martínez-Blanco, Ana M. Torres, Natalia Martínez-García, Miguel Torralba, Jorge Mateo
    Metabolites.2025; 16(1): 8.     CrossRef
  • Clinicopathological profile of gastrointestinal tract malignancies: A retrospective study.
    Bhupendra Singh Chahar, Gull Mohammad Mohammad Bhat, Ram Krishna, Anushree Chaturvedi, Chander Dutti, Sourav Debnath, Naman Bansal
    Asian Journal of Oncology.2025; 11: 23.     CrossRef
  • Immunotherapy as a Complement to Surgical Management of Hepatocellular Carcinoma
    Susan J. Kim, Kaelyn C. Cummins, Allan Tsung
    Cancers.2024; 16(10): 1852.     CrossRef
  • Inflammatory Response in the Pathogenesis and Treatment of Hepatocellular Carcinoma: A Double-Edged Weapon
    Linda Galasso, Lucia Cerrito, Valeria Maccauro, Fabrizio Termite, Irene Mignini, Giorgio Esposto, Raffaele Borriello, Maria Elena Ainora, Antonio Gasbarrini, Maria Assunta Zocco
    International Journal of Molecular Sciences.2024; 25(13): 7191.     CrossRef
  • Impacts of smoking on alcoholic liver disease: a nationwide cohort study
    Jeong-Ju Yoo, Dong Hyeon Lee, Sang Gyune Kim, Jae Young Jang, Young Seok Kim, Log Young Kim
    Frontiers in Public Health.2024;[Epub]     CrossRef
  • Contemporary epidemiology of hepatocellular carcinoma: understanding risk factors and surveillance strategies
    Fouad Jaber, George Cholankeril, Hashem B El-Serag
    Journal of the Canadian Association of Gastroenterology.2024; 7(5): 331.     CrossRef
  • Development and validation of a prognostic nomogram to predict the recurrence of AFP-negative and DCP-positive hepatocellular carcinoma after curative resection
    Junnan Li, Qi Wang, Yadong Yan, Lina Sun, Gongming Zhang, Guangming Li, Ronghua Jin
    Frontiers in Oncology.2024;[Epub]     CrossRef
  • Biomarker discovery in hepatocellular carcinoma (HCC) for personalized treatment and enhanced prognosis
    Baofa Yu, Wenxue Ma
    Cytokine & Growth Factor Reviews.2024; 79: 29.     CrossRef
  • Mapping the Hidden Terrain of Hepatocellular Carcinoma: Exploring Regional Differences in Incidence and Mortality across Two Decades by Using the Largest US Datasets
    Yazan Abboud, Vraj P. Shah, Michael Bebawy, Ahmed Al-Khazraji, Kaveh Hajifathalian, Paul J. Gaglio
    Journal of Clinical Medicine.2024; 13(17): 5256.     CrossRef
  • Bridging hope: Retrospective analysis of stereotactic radiotherapy in patients with hepatocellular carcinoma-A promising and cost-effective solution for low-and middle-income countries
    Rakesh Kapoor, Treshita Dey, Divya Khosla, Sunil Taneja, Naveen Kalra, Rajesh Gupta
    Cancer Research, Statistics, and Treatment.2024; 7(3): 326.     CrossRef
  • Absence of Survival Impact from Hepatitis During Immunotherapy in 193 Patients with Advanced Hepatocellular Carcinoma – An Observational Study from Taiwan
    Chi-Han Lin, Yung-Chia Kuo, Hsuan-Chih Kuo, Ching-Ting Wang, Shi-Ming Lin, Alan Chao-Wei Lee, Ming-Chin Yu, Wei-Chen Lee, Cherry Chiao-Erh Chen, Jason Chia-Hsun Hsieh
    Journal of Hepatocellular Carcinoma.2024; Volume 11: 1875.     CrossRef
  • A Potential Pneumothorax Induced by Immune Checkpoint Inhibitors: A Case Report and Literature Review
    Yoon-E Shin, Hyuk Kim, Jeong-Ju Yoo, Sang Gyune Kim, Young Seok Kim
    Medicina.2024; 60(10): 1634.     CrossRef
  • Management of non-alcoholic fatty liver disease-associated hepatocellular carcinoma
    Peijun Xu, Maoyun Liu, Miao Liu, Ai Shen
    BioScience Trends.2024; 18(5): 431.     CrossRef
  • Gene targets with therapeutic potential in hepatocellular carcinoma
    Syifaus Shodry, Yuliono Trika Nur Hasan, Iwal Reza Ahdi, Zulvikar Syambani Ulhaq
    World Journal of Gastrointestinal Oncology.2024; 16(12): 4543.     CrossRef
  • Evolving epidemiology of non-alcoholic fatty liver disease in South Korea: incidence, prevalence, progression, and healthcare implications from 2010 to 2022
    Jae Woo Park, Jeong-Ju Yoo, Dong Hyeon Lee, Young Chang, Hoongil Jo, Young Youn Cho, Sangheun Lee, Log Young Kim, Jae Young Jang
    The Korean Journal of Internal Medicine.2024; 39(6): 931.     CrossRef
  • Pathogenesis and management of metabolic dysfunction-associated steatohepatitis-related hepatocellular carcinoma: a narrative review
    Han Ah Lee
    The Ewha Medical Journal.2024;[Epub]     CrossRef
  • Lower Incidence of Hepatocellular Carcinoma with Tenofovir Alafenamide in Chronic Hepatitis B: Evidence from a Large-Scale Cohort
    Hye-Jin Yoo, Jae-Young Kim, Jeong-Ju Yoo, Hye Won Lee, Sang Gyune Kim, Young Seok Kim
    JHEP Reports.2024; : 101268.     CrossRef
  • Microwave ablation versus single-needle radiofrequency ablation for the treatment of HCC up to 4 cm: A randomized control trial
    Katsutoshi Sugimoto, Kento Imajo, Hidekatsu Kuroda, Go Murohisa, Kazue Shiozawa, Kentaro Sakamaki, Takuya Wada, Hirohito Takeuchi, Kei Endo, Tamami Abe, Takashi Matsui, Takahiro Murakami, Masato Yoneda, Atsushi Nakajima, Shigehiro Kokubu, Takao Itoi
    JHEP Reports.2024; : 101269.     CrossRef
  • The histopathological and molecular heterogeneity of hepatocellular carcinoma: a narrative review
    Wonju Chung, Haeryoung Kim
    The Ewha Medical Journal.2024;[Epub]     CrossRef
  • Enhancing global hepatocellular carcinoma management: Bridging Eastern and Western perspectives on dexamethasone and N-acetylcysteine before transarterial chemoembolization
    Thang Viet Luong, Nam Van Duc Nguyen, Linh Duy Le, Hieu Nguyen Hoang Minh, Hai Nguyen Ngoc Dang
    World Journal of Gastroenterology.2024; 30(47): 4983.     CrossRef
  • Predicting Microvascular Invasion in Liver Transplant Recipients for Hepatocellular Carcinoma
    Usman I Aujla, Imran Ali Syed, Kashif Rafi, Ammara Naveed, Ahmad K Malik, Muhammad Yasir Khan, Ihsan Ul Haq, Sohail Rashid, Osama T Butt, Faisal Dar
    Cureus.2024;[Epub]     CrossRef
  • The Influence of Sex and Age on Survival in Patients with Hepatocellular Carcinoma
    Iuliana Pompilia Radu, Bernhard Scheiner, Jonas Schropp, Maria Gabriela Delgado, Birgit Schwacha-Eipper, Chaonan Jin, Jean-Francois Dufour, Matthias Pinter
    Cancers.2024; 16(23): 4023.     CrossRef
  • Chronic Hepatitis C Infection Treated with Direct-Acting Antiviral Agents and Occurrence/Recurrence of Hepatocellular Carcinoma: Does It Still Matter?
    Carlo Smirne, Maria Grazia Crobu, Irene Landi, Nicole Vercellino, Daria Apostolo, David James Pinato, Federica Vincenzi, Rosalba Minisini, Stelvio Tonello, Davide D’Onghia, Antonio Ottobrelli, Silvia Martini, Christian Bracco, Luigi Maria Fenoglio, Mauro
    Viruses.2024; 16(12): 1899.     CrossRef
  • Statin use and liver-related prognosis among patients with MASLD
    Byungyoon Yun, Heejoo Park, Jian Lee, Beom Kyung Kim, Jin-Ha Yoon
    JHEP Reports.2024; : 101313.     CrossRef
  • Long-term results of surgical treatment of hepatocellular cancer in Russian real practice
    V. V. Petkau, R. I. Rasulov, A. A. Muratov, G. V. Nurbekyan, I. B. Uvarov, A. A. Kirshin, R. V. Orlova, N. V. Popova, M. S. Dinikin, R. Yu. Khlobystin, A. V. Sultanbaev, K. V. Menshikov, O. G. Orlov
    Meditsinskiy sovet = Medical Council.2024; (21): 114.     CrossRef
  • Overall Survival and the Impact of Albumin-bilirubin Grade in Patients with Advanced Hepatocellular Carcinoma: Data from a Tertiary Care Hospital in a Lower-middle-income Country
    Mohammad SS Naviwala, Waqas A Khan, Adeeba Zaki, Mahnoor Tariq, Faiza Ahmed, Warda Saleem, Munira Moosajee, Yasmin A Rashid
    Euroasian journal of hepato-gastroenterology.2024; 14(2): 251.     CrossRef
  • The roles and mechanisms of miRNA in HBV-HCC carcinogenesis: Why no therapeutic agents after 30 years?
    KURT SARTORIUS, BENN SARTORIUS, CHERIE WINKLER, ANIL CHUTURGOON, ANNA KRAMVIS, PING AN, WEIGANG ZHANG, YUNJIE LU
    BIOCELL.2024; 48(11): 1543.     CrossRef
Close layer
Original Articles
Treatment options for solitary hepatocellular carcinoma ≤5 cm: surgery vs. ablation: a multicenter retrospective study
Kazuya Kariyama, Kazuhiro Nouso, Atsushi Hiraoka, Hidenori Toyoda, Toshifumi Tada, Kunihiko Tsuji, Toru Ishikawa, Takeshi Hatanaka, Ei Itobayashi, Koichi Takaguchi, Akemi Tsutsui, Atsushi Naganuma, Satoshi Yasuda, Satoru Kakizaki, Akiko Wakuta, Shohei Shiota, Masatoshi Kudo, Takashi Kumada
J Liver Cancer. 2024;24(1):71-80.   Published online November 6, 2023
DOI: https://doi.org/10.17998/jlc.2023.09.11
  • 10,377 Views
  • 215 Downloads
  • 5 Web of Science
  • 4 Citations
AbstractAbstract PDF
Background/Aim
The aim of this study was to compare the therapeutic efficacy of ablation and surgery in solitary hepatocellular carcinoma (HCC) measuring ≤5 cm with a large HCC cohort database.
Methods
The study included consecutive 2,067 patients with solitary HCC who were treated with either ablation (n=1,248) or surgery (n=819). Th e patients were divided into three groups based on the tumor size and compared the outcomes of the two therapies using propensity score matching.
Results
No significant difference in recurrence-free survival (RFS) or overall survival (OS) was found between surgery and ablation groups for tumors measuring ≤2 cm or >2 cm but ≤3 cm. For tumors measuring >3 cm but ≤5 cm, RFS was significantly better with surgery than with ablation (3.6 and 2.0 years, respectively, P=0.0297). However, no significant difference in OS was found between surgery and ablation in this group (6.7 and 6.0 years, respectively, P=0.668).
Conclusion
The study suggests that surgery and ablation can be equally used as a treatment for solitary HCC no more than 3 cm in diameter. For HCCs measuring 3-5 cm, the OS was not different between therapies; thus, ablation and less invasive therapy can be considered a treatment option; however, special caution should be taken to prevent recurrence.

Citations

Citations to this article as recorded by  
  • Asian Conference on Tumor Ablation Guidelines for Hepatocellular Carcinoma
    Shuichiro Shiina, Ryosuke Tateishi, Joon Il Choi, So Yeon Kim, Zhiqiang Meng, Lujun Shen, Sheng-Nan Lu, Jen-I. Hwang, Maki Tobari, Hitoshi Maruyama, Terguunbileg Batsaikhan, Qing Deng, Lariza Marie Canseco, Yoshinari Asaoka, Shi-Ming Lin, Kai-Wen Huang, H
    Liver Cancer.2025; 14(5): 651.     CrossRef
  • Reply to the Letter regarding “Treatment options for solitary hepatocellular carcinoma ≤5 cm: surgery vs. ablation: a multicenter retrospective study”
    Kazuhiro Nouso, Kazuya Kariyama
    Journal of Liver Cancer.2024; 24(1): 5.     CrossRef
  • Radiofrequency for hepatocellular carcinoma larger than 3 cm: potential for applications in daily practice
    Ji Hoon Kim, Pil Soo Sung
    Journal of Liver Cancer.2024; 24(1): 1.     CrossRef
  • Letter regarding “Treatment options for solitary hepatocellular carcinoma ≤5 cm: surgery vs. ablation: a multicenter retrospective study”
    Jongman Kim
    Journal of Liver Cancer.2024; 24(1): 3.     CrossRef
Close layer
Comparison of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma with portal vein tumor thrombosis
Jeayeon Park, Yun Bin Lee, Yunmi Ko, Youngsu Park, Hyunjae Shin, Moon Haeng Hur, Min Kyung Park, Dae-Won Lee, Eun Ju Cho, Kyung-Hun Lee, Jeong-Hoon Lee, Su Jong Yu, Tae-Yong Kim, Yoon Jun Kim, Tae-You Kim, Jung-Hwan Yoon
J Liver Cancer. 2024;24(1):81-91.   Published online January 19, 2024
DOI: https://doi.org/10.17998/jlc.2023.12.25
  • 12,474 Views
  • 315 Downloads
  • 12 Web of Science
  • 12 Citations
AbstractAbstract PDFSupplementary Material
Background/Aim
Atezolizumab plus bevacizumab and lenvatinib are currently available as first-line therapy for the treatment of unresectable hepatocellular carcinoma (HCC). However, comparative efficacy studies are still limited. This study aimed to investigate the effectiveness of these treatments in HCC patients with portal vein tumor thrombosis (PVTT).
Methods
We retrospectively included patients who received either atezolizumab plus bevacizumab or lenvatinib as first-line systemic therapy for HCC with PVTT. Primary endpoint was overall survival (OS), and secondary endpoints included progressionfree survival (PFS) and disease control rate (DCR) determined by response evaluation criteria in solid tumors, version 1.1.
Results
A total of 52 patients were included: 30 received atezolizumab plus bevacizumab and 22 received lenvatinib. The median follow-up duration was 6.4 months (interquartile range, 3.9-9.8). The median OS was 10.8 months (95% confidence interval [CI], 5.7 to not estimated) with atezolizumab plus bevacizumab and 5.8 months (95% CI, 4.8 to not estimated) with lenvatinib (P=0.26 by log-rank test). There was no statistically significant difference in OS (adjusted hazard ratio [aHR], 0.71; 95% CI, 0.34-1.49; P=0.37). The median PFS was similar (P=0.63 by log-rank test), with 4.1 months (95% CI, 3.3-7.7) for atezolizumab plus bevacizumab and 4.3 months (95% CI, 2.6-5.8) for lenvatinib (aHR, 0.93; 95% CI, 0.51-1.69; P=0.80). HRs were similar after inverse probability treatment weighting. The DCRs were 23.3% and 18.2% in patients receiving atezolizumab plus bevacizumab and lenvatinib, respectively (P=0.74).
Conclusion
The effectiveness of atezolizumab plus bevacizumab and lenvatinib was comparable for the treatment of HCC with PVTT.

Citations

Citations to this article as recorded by  
  • Role of Liver Function in the Multiparametric Assessment of Hepatocellular Carcinoma
    Fabio Melandro, Leonardo Centonze, Ciro Celsa, Simone Famularo, Davide Ghinolfi, Silvia Nardelli, Maria Pallozzi, Ludovico Abenavoli, Fabrizio Romano, Francesca Romana Ponziani, Francesco Paolo Russo, Quirino Lai
    Medicina.2026; 62(1): 138.     CrossRef
  • Combined Transarterial Chemoembolization and External Beam Radiotherapy for Identifying Surgical Candidates for Hepatocellular Carcinoma with Macroscopic Vascular Invasion: A Propensity Score–Weighted Analysis
    Sumin Lee, Jinhong Jung, Jonggi Choi, So Yeon Kim, Jin Hyoung Kim, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim, Han Chu Lee, Gi-Won Song, Jin-hong Park, Sang Min Yoon
    Cancer Research and Treatment.2026; 58(1): 275.     CrossRef
  • Immunotherapy in Hepatocellular Carcinoma with Portal Vein Tumour Thrombosis: From Poor Prognosis to Curative-Intent Strategies
    Luca Marzi, Rodolfo Sacco, Luisa Siciliani, Saveria Lory Crocè, Mauro Giuffrè, Cristina Stasi, Chiara Turri, Monica Zoeschg, Andrea Mega
    Cancers.2026; 18(4): 627.     CrossRef
  • Survival Outcomes Following Yttrium-90 and Holmium-166 Transarterial Radioembolization for Hepatocellular Carcinoma
    Dávid Ádám Korda, Dénes Balázs Horváthy, Sándor Czibor, Domonkos Nádasdy-Horváth, Petra Sólymos, Oszkár Háhn, Bálint Tegze, Klára Werling, Attila Jakó, Szabolcs Takács, Pál Ákos Deák, András Bibok
    Cancers.2026; 18(13): 2039.     CrossRef
  • Management strategies for advanced hepatocellular carcinoma with portal vein tumor thrombosis
    Jeayeon Park, Su Jong Yu
    The Ewha Medical Journal.2025;[Epub]     CrossRef
  • Case Report: Tumor lysis syndrome in advanced, massive hepatocellular carcinoma with main portal vein invasion following atezolizumab plus bevacizumab therapy
    Tien-Shin Chou, Chun-Feng Wu, Chih-Lang Lin, Chao-Wei Hsu
    Frontiers in Oncology.2025;[Epub]     CrossRef
  • Locoregional therapy combined with targeted therapy and immunotherapy for hepatocellular carcinoma with portal vein tumor thrombosis: a systematic review and meta-analysis
    Mengjie Jiang, Chao Chen, Yujie Hu, Gang Lin, Huafeng Li
    Scientific Reports.2025;[Epub]     CrossRef
  • Liver Resection versus Targeted Therapy Plus PD-1 Inhibitors in Hepatocellular Carcinoma with Type I-II Portal Vein Tumor Thrombus: A Comparative Study
    Liang Li, Zhenli Li, Yibing Zhang, Shuaishuai Zhu, Yuanzhi Ni, Lindi Xu, Shixing Yan, Yufu Tang
    Journal of Hepatocellular Carcinoma.2025; Volume 12: 2745.     CrossRef
  • Prognostic Significance of Glypican-3 Expression in Hepatocellular Carcinoma Treated with Atezolizumab-Bevacizumab
    Ji Hoon Kim, Ji Won Han, Hee Sun Cho, Jeong Won Jang, Kwon Yong Tak, Pil Soo Sung
    Cancers.2025; 17(24): 3967.     CrossRef
  • Portal vein tumor thrombosis in hepatocellular carcinoma patients: Is it the end?
    Walaa Abdelhamed, Hend Shousha, Mohamed El-Kassas
    Liver Research.2024;[Epub]     CrossRef
  • Reappraisal of transarterial radioembolization for liver-confined hepatocellular carcinoma with portal vein tumor thrombosis: Editorial on “Transarterial radioembolization versus tyrosine kinase inhibitor in hepatocellular carcinoma with portal vein throm
    Jin Hyoung Kim, Gun Ha Kim, Dong Il Gwon
    Clinical and Molecular Hepatology.2024; 30(4): 659.     CrossRef
  • Current perspectives on the pharmacological treatment of advanced hepatocellular carcinoma: a narrative review
    Hye-Jin Yoo, Jeong-Ju Yoo, Sang Gyune Kim, Young Seok Kim
    The Ewha Medical Journal.2024;[Epub]     CrossRef
Close layer
Additional nodules detected using EOB-MRI in patients with resectable single hepatocellular carcinoma: an implication for active treatment strategy
Na Reum Kim, Seoung Yoon Rho, Jonathan Navarro, Chansik An, Dai Hoon Han, Jin Sub Choi, Myeong-Jin Kim, Gi Hong Choi
J Liver Cancer. 2024;24(1):92-101.   Published online February 14, 2024
DOI: https://doi.org/10.17998/jlc.2024.01.25
  • 7,036 Views
  • 122 Downloads
  • 2 Web of Science
  • 2 Citations
AbstractAbstract PDF
Background/Aim
Gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging (EOBMRI) further enhances the identification of additional hepatic nodules compared with computed tomography (CT) alone; however, the optimal treatment for such additional nodules remains unclear. We investigated the long-term oncological effect of aggressive treatment strategies for additional lesions identified using EOB-MRI in patients with hepatocellular carcinoma (HCC).
Methods
Data from 522 patients diagnosed with solitary HCC using CT between January 2008 and December 2012 were retrospectively reviewed. Propensity score-matched (PSM) analysis was used to compare the oncologic outcomes between patients with solitary HCC and those with additional nodules on EOB-MRI after aggressive treatment (resection or radiofrequency ablation [RFA]).
Results
Among the 383 patients included, 59 had additional nodules identified using EOB-MRI. Compared with patients with solitary HCC, those with additional nodules on EOB-MRI had elevated total bilirubin, aspartate transaminase, and alanine transaminase; had a lower platelet count, higher MELD score, and highly associated with liver cirrhosis (P<0.05). Regarding long-term outcomes, 59 patients with solitary HCC and those with additional nodules after PSM were compared. Disease-free survival (DFS) and overall survival (OS) were comparable between the two groups (DFS, 60.4 vs. 44.3 months, P=0.071; OS, 82.8 vs. 84.8 months, P=0.986).
Conclusion
The aggressive treatment approach, either resection or RFA, for patients with additional nodules identified on EOBMRI was associated with long-term survival comparable with that for solitary HCC. However, further studies are required to confirm these findings.

Citations

Citations to this article as recorded by  
  • Comparison of Gd-EOB-DTPA-enhanced MRI versus multiphasic enhanced CT for detecting occult recurrence after curative ablation of hepatocellular carcinoma
    Zhi Zhu, Mingyu Zhang, Fengcan Cai, Yuanyong Zhou, Qingde Wu
    Frontiers in Oncology.2026;[Epub]     CrossRef
  • Differential Infiltration of T-Cell Populations in Tumor and Liver Tissues Predicts Recurrence-Free Survival in Surgically Resected Hepatocellular Carcinoma
    Eun Ji Jang, Ho Joong Choi, Young Kyoung You, Deok Hwa Seo, Mi Hyun Kwon, Keungmo Yang, Jaejun Lee, Jeong Won Jang, Seung Kew Yoon, Ji Won Han, Pil Soo Sung
    Cancers.2025; 17(9): 1548.     CrossRef
Close layer
Liver resection in selective hepatocellular carcinoma with Vp3 or Vp4 portal vein tumor thrombosis improves prognosis
Manuel Lim, Jongman Kim, Jinsoo Rhu, Gyu-Seong Choi, Jae-Won Joh
J Liver Cancer. 2024;24(1):102-112.   Published online February 14, 2024
DOI: https://doi.org/10.17998/jlc.2024.01.31
  • 10,212 Views
  • 123 Downloads
  • 4 Web of Science
  • 5 Citations
AbstractAbstract PDF
Background/Aim
Hepatocellular carcinoma (HCC) tumor thrombi located in the first branch of the portal vein (Vp3) or in the main portal trunk (Vp4) are associated with poor prognosis. This study aimed to investigate the clinicopathological characteristics and risk factors for HCC recurrence and mortality following liver resection (LR) in patients with Vp3 or Vp4 HCC.
Methods
The study included 64 patients who underwent LR for HCC with Vp3 or Vp4 portal vein tumor thrombosis (PVTT).
Results
Fifty-eight patients (90.6%) had Vp3 PVTT, whereas the remaining six patients exhibited Vp4 PVTT. The median tumor size measured 8 cm, with approximately 36% of patients presented with multiple tumors. Fifty-four patients (84.4%) underwent open LR, whereas 10 patients underwent laparoscopic LR. In the Vp4 cases, combined LR and tumor thrombectomy were performed. The 3-year cumulative disease-free survival rate was 42.8% for the Vp3 group and 22.2% for the Vp4 group. The overall survival (OS) rate at 3 years was 47.9% for the Vp3 group and 60.0% for the Vp4 group. Intrahepatic metastasis has been identified as an important contributor to HCC recurrence. High hemoglobin levels are associated with high mortality.
Conclusion
LR is a safe and effective treatment modality for selected patients with Vp3 or Vp4 HCC PVTT. This suggests that LR is a viable option for these patients, with favorable outcomes in terms of OS.

Citations

Citations to this article as recorded by  
  • Survival benefit of resectability determined by multiple surgeons in BCLC-C Stage: A single-center cohort study
    Kyung Chul Yoon, Sanggyun Suh, YoungRok Choi, Jeong-Moo Lee, Minseob Kim, Jaewon Lee, Jae-Yoon Kim, Jiyoung Kim, Won-Gun Yun, Chang-Sup Lim, Su young Hong, Suk Kyun Hong, Nam-Joon Yi, Kwang-Woong Lee, Kyung-Suk Suh
    Surgical Oncology.2026; 64: 102328.     CrossRef
  • Expert consensus on the selection of surgical treatment modalities for hepatocellular carcinoma (fourth revision)
    Xiaoping Chen
    Oncology and Translational Medicine.2026; 12(3): 117.     CrossRef
  • Redefining Liver Transplantation Indications for Hepatic Malignancies in the Era of Precision Transplant Oncology: An Up-to-Date Narrative Review
    Mario Romeo, Fiammetta Di Nardo, Carmine Napolitano, Paolo Vaia, Claudio Basile, Giusy Senese, Annachiara Coppola, Patrizia Iodice, Simone Olivieri, Alessandro Federico, Marcello Dallio
    Journal of Clinical Medicine.2026; 15(10): 3579.     CrossRef
  • Preoperative HAIC enlarges future liver remnant in initial unresectable HCC patients with Vp3 tumor thrombus
    Yifan Zhang, Yiquan Lu, Yuchen Yang, Xinyi Luo, Nan Wang, Fengjie Hao, Weixia Li, Yongjun Chen, Junqing Wang
    Frontiers in Oncology.2026;[Epub]     CrossRef
  • Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment
    Soo Young Hwang, Pojsakorn Danpanichkul, Vatche Agopian, Neil Mehta, Neehar D. Parikh, Ghassan K. Abou-Alfa, Amit G. Singal, Ju Dong Yang
    Clinical and Molecular Hepatology.2025; 31(Suppl): S228.     CrossRef
Close layer

JLC : Journal of Liver Cancer
TOP